Conditions: Healthy Volunteers
Keywords: Bioavailability BMS-986177 14C-Microtracer Milvexian
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 17
Healthy volunteers: yes

Brief summary:
The purpose of this study is to evaluate the absolute oral bioavailability (amount of drug entering the bloodstream) of spray-dried dispersion (SDD) milvexian capsules in the fed and fasted states, and to bridge the exposures seen using only the oral solution.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: BMS-986177 Oral Solution intervention 2: [14C]BMS-986177 Solution for Infusion intervention 3: BMS-986177 Spray-dried Dispersion Capsules
Intervention descriptions: intervention 1: Specified dose on specified days intervention 2: Specified dose on specified days intervention 3: Specified dose on specified days

Protocol document:
Prot_SAP_000.pdf: 
Official Title of Study: 
A Study to Assess the Absolute Oral Bioavailability of Milvexian Using a 14C-Microtracer and 
Oral Solution in Healthy Participants with Additional Food Effect Comparison of a Spray-Dried 
Dispersion Formulation of Milvexian in Capsules 
 
 
NCT Number: NCT04965389 
Document Date (Date in which document was last revised): 14-Apr-2021 


Page:
1
Protocol Number:
CV010-062
Date:
14-Apr-2021
CLINICAL PROTOCOL CV010-062
A Study to Assess the Absolute Oral Bioavailability of Milvexian Using a 14C-Microtracer and 
Oral Solution in Healthy Participants with Additional Food Effect Comparison of a Spray-Dried 
Dispersion Formulation of Milvexian in Capsules
Brief Title:
Absolute Oral Bioavailability Study of Milvexian Using an IV Microtracer with Additional 
Formulation and Food Effect Comparison
Clinical Trial Physician - Medical Monitor
Primary Medical Monitor
 
Local Medical Monitor 
24-hr Emergency Telephone Number
USA: 
International: 
Bristol Myers Squibb Company
Route 206 & Province Line Road
Lawrenceville, NJ 08543
Avenue de Finlande 4
B-1420 Braine-l’Alleud, Belgium
24-hr Emergency Numbers 
Phone:  
Fax: 
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Date: 14 April 2021
2
REGULATORY AGENCY IDENTIFIER NUMBER(S)
EudraCT: 2021-000892-35
This document is the confidential and proprietary information of Bristol Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (eg, amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document. Any person who receives 
this document without due authorization from BMS is requested to return it to BMS or 
promptly destroy it. References to BMS in this protocol may apply to partners to which BMS 
has transferred obligations (eg, a Contract Research Organization [CRO]).
© 2021 Bristol Myers Squibb Company
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Date: 14 April 2021
3
DOCUMENT HISTORY
Document
Date of Issue
Summary of Change
Original Protocol
14 April 2021
Not applicable



3
Approved
1.0
v
Approved
1.0
v


TABLE OF CONTENTS 
 
 
TITLE PAGE ................................................................................................................ 
 
DOCUMENT HISTORY .............................................................................................. 
 
TABLE OF CONTENTS .............................................................................................. 
 
1 PROTOCOL SUMMARY ......................................................................................... 
 
2 SCHEDULE OF ACTIVITIES.................................................................................. 
 
3 INTRODUCTION ..................................................................................................... 
 
3.1 Background ....................................................................................................... 
 
3.1.1 Clinical Pharmacology and Safety .......................................................... 
 
3.2 Study Rationale ................................................................................................. 
 
3.2.1 Pharmacokinetics ..................................................................................... 
 
3.2.2 Pharmacodynamics .................................................................................. 
 
3.2.3 Safety and Tolerability ............................................................................. 
 
3.3 Benefit/Risk Assessment .................................................................................. 
 
3.3.1 Risk Assessment ....................................................................................... 
 
3.3.2 COVID-19 Related Risks and Risk Mitigation Measures ........................ 
 
3.3.2.1 IMP Related Risk ............................................................................ 
 
3.3.2.2 General COVID-19 Related Risk Mitigation Measures ................. 
 
3.3.2.3 COVID-19 Vaccine-Related Risk .................................................... 
 
3.3.3 Benefit Assessment ................................................................................... 
 
3.3.4 Overall Benefit/Risk Conclusion .............................................................. 
 
4 OBJECTIVES AND ENDPOINTS ........................................................................... 
 
5 STUDY DESIGN....................................................................................................... 
 
5.1 Overall Design .................................................................................................. 
 
5.1.1 Data Monitoring Committee and Other Committees ............................... 
 
5.2 Number of Participants ..................................................................................... 
 
5.3 End of Study Definition .................................................................................... 
 
5.4 Scientific Rationale for Study Design............................................................... 
 
6 STUDY POPULATION ............................................................................................ 
 
6.1 Inclusion Criteria .............................................................................................. 
 
6.2 Exclusion Criteria ............................................................................................. 
 
6.3 Lifestyle Restrictions ........................................................................................ 
 
6.3.1 Meals and Dietary Restrictions ............................................................... 
 
6.3.2 Other Dietary Restrictions ....................................................................... 
 
6.3.3 Caffeine, Alcohol and Tobacco ................................................................ 
 
6.3.4 Activity ..................................................................................................... 
 
6.4 Screen Failures .................................................................................................. 
 
6.4.1 Retesting During Screening or Lead-in Period ....................................... 
 
6.4.2 Activity ..................................................................................................... 
 
7 STUDY INTERVENTIONS AND CONCOMITANT THERAPY .......................... 
 
7.1 Study Interventions Administered .................................................................... 
 
7.2 Method of Study Intervention Assignment ....................................................... 
 
7.3 Blinding............................................................................................................. 
 
7.4 Dosage Modification ......................................................................................... 
 
1
3
4
7
12
18
19
19
20
20
21
21
22
22
23
23
23
24
24
24
24
25
25
26
26
27
27
29
29
30
33
33
34
34
34
35
35
35
35
36
37
37
37
Clinical Protocol
BMS-986177
CV010-062
Milvexian
Date: 14 April 2021
4
Approved
1.0
v
Approved
1.0
v


7.5 Preparation/Handling/Storage/Accountability .................................................. 
 
7.6 Treatment Compliance ...................................................................................... 
 
7.7 Concomitant Therapy........................................................................................ 
 
7.7.1 Prohibited and/or Restricted Treatments................................................. 
 
7.8 Continued Access to Study Intervention After the End of the Study ............... 
 
8 DISCONTINUATION CRITERIA ........................................................................... 
 
8.1 Discontinuation From Study Intervention ........................................................ 
 
8.1.1 Stopping Criteria ..................................................................................... 
 
8.1.2 Study Termination .................................................................................... 
 
8.1.3 Post-study Intervention Study Follow-up................................................. 
 
8.2 Discontinuation From the Study ....................................................................... 
 
8.2.1 Individual Discontinuation Criteria ........................................................ 
 
8.3 Lost to Follow-up .............................................................................................. 
 
9 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 
 
9.1 Efficacy Assessments ........................................................................................ 
 
9.2 Adverse Events ................................................................................................. 
 
9.2.1 Time Period and Frequency for Collecting AE and SAE Information .... 
 
9.2.2 Method of Detecting AEs and SAEs ......................................................... 
 
9.2.3 Follow-up of AEs and SAEs ..................................................................... 
 
9.2.4 Regulatory Reporting Requirements for SAEs ......................................... 
 
9.2.5 Reporting of COVID-19 Vaccine-Related Adverse Events ...................... 
 
9.2.6 Pregnancy ................................................................................................ 
 
9.2.7 Laboratory Test Result Abnormalities ..................................................... 
 
9.2.8 Potential Drug-induced Liver Injury ....................................................... 
 
9.2.9 Other Safety Considerations .................................................................... 
 
9.3 Overdose ........................................................................................................... 
 
9.4 Safety ................................................................................................................ 
 
9.4.1 Physical Examinations ............................................................................. 
 
9.4.2 Vital signs................................................................................................. 
 
9.4.3 Electrocardiograms ................................................................................. 
 
9.4.4 Clinical Safety Laboratory Assessments .................................................. 
 
9.4.5 Physical Measurements ........................................................................... 
 
9.5 Pharmacokinetics .............................................................................................. 
 
9.6 Immunogenicity Assessments ........................................................................... 
 
9.7 Genetics............................................................................................................. 
 
 
9.9 Additional Research .......................................................................................... 
 
9.10 Other Assessments .......................................................................................... 
 
9.11 Health Economics ........................................................................................... 
 
10 STATISTICAL CONSIDERATIONS .................................................................... 
 
10.1 Statistical Hypotheses ..................................................................................... 
 
10.2 Sample Size Determination ............................................................................. 
 
10.3 Analysis Sets ................................................................................................... 
 
10.4 Statistical Analyses ......................................................................................... 
 
10.4.1 Primary Endpoint................................................................................... 
 
10.4.2 Secondary Endpoints ............................................................................. 
 
37
38
38
38
39
39
39
40
41
41
41
42
42
43
43
43
44
44
44
44
45
45
45
45
46
46
46
46
46
47
47
49
49
52
52
52
52
52
52
52
52
53
53
53
54
Clinical Protocol
BMS-986177
CV010-062
Milvexian
Date: 14 April 2021
5
Approved
1.0
v
Approved
1.0
v


10.4.3 Exploratory Endpoint(s) ........................................................................ 
 
10.4.4 Other Safety Analysis ............................................................................. 
 
10.4.5 Other Analyses ....................................................................................... 
 
10.5 Interim Analyses ............................................................................................. 
 
11 REFERENCES ........................................................................................................ 
 
12 APPENDICES ......................................................................................................... 
 
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ........................................ 
 
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS ................................. 
 
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW-UP, AND REPORTING ....................................................................... 
 
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ..................................................................... 
 
 
55
55
55
55
56
57
58
60
69
73
Clinical Protocol
BMS-986177
CV010-062
Milvexian
Date: 14 April 2021
6
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
1
PROTOCOL SUMMARY
Protocol Title:
A Study to Assess the Absolute Oral Bioavailability of Milvexian Using a 14C-Microtracer and 
Oral Solution in Healthy Participants with Additional Food Effect Comparison of a Spray-Dried 
Dispersion Formulation of Milvexian in Capsules 
Brief Title: Absolute Oral Bioavailability Study of Milvexian Using an IV Microtracer with 
Additional Formulation and Food Effect Comparison
Rationale:
This study is being conducted to evaluate the absolute oral bioavailability of milvexian (known as 
BMS-986177 or JNJ-70033093) when administered as the spray-dried dispersion (SDD) in 
capsule formulation and an oral solution formulation. Additionally, fed and fasted state 
bioavailability comparisons of the capsule formulation will be conducted, at a clinically relevant 
dose range.
Objectives and Endpoints: 
Objectives
Endpoints
Primary
Primary
•
To assess the absolute oral bioavailability of 
 doses of milvexian administered as: a 
 mg solution (fasted), 
mg SDD capsule 
(fed and fasted) and 
mg SDD capsule (fed
and fasted), to healthy participants
•
Absolute oral bioavailability (F) for each treatment
Date: 14 April 2021
7
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Objectives
Endpoints
Secondary
Secondary
•
To characterize the IV and the oral PK of 
milvexian following 
 administration in 
the fed and fasted states to healthy participants
•
Cmax, Tmax, AUC(0-T), AUC(INF), CLT or CLT/F, 
CLR, Vz or Vz/F, Ae, %UR, T-HALF, for each 
treatment
•
MRT and Vss of [14C]milvexian following an IV dose
•
Frel for each SDD capsule treatment vs oral solution 
formulation
•
Food effect with 
mg and 
 mg SDD capsules based 
on ratios of Cmax, AUC(0-T), and AUC(INF)
•
To assess the safety and tolerability of 
milvexian
following 
 oral and IV 
administration, to healthy participants
•
Occurrence of AEs and SAEs, abnormalities in vital 
sign measurements exceeding pre-defined thresholds, 
findings on ECGs and physical examinations, and 
abnormalities in clinical laboratory tests
CLR: renal clearance; CLT: total clearance; CLT/F: apparent clearance of drug after extravascular administration;
Cmax: maximum observed concentration; ECG: electrocardiogram; Frel: relative bioavailability; IV: 
intravenous; MRT: mean residence time; T-HALF: half-life; Tmax: time of maximum observed concentration; 
%UR: percent urinary recovery; Vss: volume of distribution at steady state; Vz: volume of distribution of 
terminal phase; Vz/F: apparent volume of distribution at terminal phase after extravascular administration.
Overall Design:
•
This is a Phase 1, open-label, partially randomized, 
period crossover study to evaluate the 
absolute bioavailability of milvexian following oral administration of a 
 dose of the oral
solution in conjunction with a 14C microdose given at the time of maximum observed 
concentration (Tmax) of the oral solution when fasted, and crossover 
 doses of SDD 
capsules at two dose levels in the fed and fasted state across 
treatment periods in healthy 
volunteers.
•
Participants will undergo screening evaluations to determine study eligibility within 
 days 
prior to initial administration of study treatment (Day , Treatment Period ). Participants will 
be admitted to the clinical facility on the morning of Day
 of Treatment Period  and will 
remain in the facility for the entire duration of the dosing treatment periods, including washout. 
•
On Day  of Treatment Period  all participants will be randomized to a treatment sequence, 
with the treatment for Treatment Period  fixed owing to logistical consideration of the 
radiolabeled investigational product.
•
Participants will be randomized to 1 of 4 treatment sequences immediately prior to 
administration of treatment in Treatment Period . A 4-sequence Latin square will be used. 
Fasted study treatments will be administered following an overnight fast of at least 10 hours 
and fed study treatments will be administered 30 minutes after the start of a high-fat a meal.
•
On the morning of Day  of Treatment Period  all participants will receive the milvexian
mg oral solution in the fasted state, followed 1 hour later by the intravenous (IV)
[14C]milvexian
 μg containing not more than (NMT)
kBq microdose infused over 
15 minutes. 
•
On the mornings of Day  for Treatment Periods 
, participants will receive milvexian
SDD capsules, 
mg in the fed and fasted states, and milvexian SDD capsules, 
mg in the 
Date: 14 April 2021
8
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
fed and fasted states, in an order according to the randomization schedule, with a minimum 
72 hour washout between dose administration in each treatment period.
•
Participants will be discharged from the clinical unit 72 hours after the final dose of study 
treatment (ie following Treatment Period ).
•
There will be a follow up phone call 5 to 7 days post-final dose to ensure the ongoing wellbeing 
of the participants.
Number of Participants:
A total of 16 participants will be randomized to ensure at least 13 participants complete the study 
and are evaluable. 
Study Population:
Healthy male volunteers or healthy female volunteers not of childbearing potential, aged 18 to 
65 years, inclusive, at the time of the signing the informed consent. 
Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, at screening.
Intervention Groups and Duration:
•
The duration of study participation is expected to be up to approximately 7 weeks (including 
screening).
•
Participants will undergo screening evaluations to determine study eligibility within 
 days 
prior to initial administration of study treatment (Day , Treatment Period ). 
•
Participants will be admitted to the clinical facility on the morning of Day 
 of Treatment 
Period  and will remain in the facility for the entire duration of the dosing treatment periods, 
including washout. 
•
There will be a follow up phone call 5 to 7 days post-final dose (ie Treatment Period  Day  
) to ensure the ongoing wellbeing of the participants.
Study intervention: 
Study Intervention for CV010-062
Medication 
Potency 
IP/Non-IP 
Duration of Dosing
BMS-986177 oral
solution
mg
mg/mL
IP
mg 
 dose on a 
 
occasion
[14C]BMS-986177 
Solution for Infusion 
μg/mL (NMT 
kBq/  mL)
μg/mL
IP
μg 
 dose on a 
 
occasion
BMS-986177 SDD 
capsules, 
mg
mg
IP
 dose on occasions; 
 in the fasted state (at 
Date: 14 April 2021
9
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Study Intervention for CV010-062
Medication 
Potency 
IP/Non-IP 
Duration of Dosing
mg and 
mg),
 in 
the fed state (at 
mg and 
mg)
IP: investigational product; NMT: not more than.
Statistical Methods
Sample size determination is based on consideration of the precision of the estimate of the 
geometric mean ratios (GMR) of the maximum observed concentration (Cmax) and area under the 
concentration-time curve (AUC) of milvexian between test and reference treatments. With 
13 evaluable participants, there will be an 80% probability that the 90% confidence interval (CI) 
of GMR will be within 80% and 125% of the point estimate. The precision estimate is based on 
the assumptions that Cmax and AUCs of milvexian are log-normally distributed with intra-subject 
coefficient of variation (CV) of no greater than 28.3%. 
 
The primary endpoint is to determine the absolute oral bioavailability for each treatment, which 
will be summarized with descriptive statistics and 90% CIs. The secondary endpoints include:
plasma PK concentrations and PK parameters, which will be summarized by treatment for 
milvexian and [14C]milvexian, as applicable; relative bioavailability assessment of the SDD 
capsule formulation versus the oral solution; fed versus fasted state bioavailability comparisons of 
the SDD capsule formulation; and additional safety information.
The statistical analysis plan (SAP) will be developed and finalized before database lock and will 
describe the selection of participants to be included in the analyses, and procedures for accounting 
for missing, unused, and spurious data. 
Data Monitoring Committee: No
A Data Monitoring Committee will not be used in the study.
Other Committee: No
Other review committee will not be used in the study.
Brief Summary:
Milvexian is being developed as an orally administered anticoagulant to prevent and treat 
atherothrombotic and thromboembolic disorders. The purpose of this study is to evaluate the 
absolute oral bioavailability of the SDD formulation of milvexian at a clinically relevant dose 
range, in the fed and fasted states and to bridge the exposures seen using the oral solution. The 
results from this study will provide insights into the understanding of milvexian PK at clinically 
relevant doses. Study details include:
Date: 14 April 2021
10
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Study Duration: Approximately 7 weeks (including screening)
Study Intervention Duration: 
 oral doses on 
occasions, and a 
 oral dose with an IV 
14C-microdose on a 
 occasion (ie  dosing occasions in total)
Study Visit Frequency: A screening visit followed by a single admission to the clinical research 
unit.
Date: 14 April 2021
11
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
2
SCHEDULE OF ACTIVITIES
Schedules of activities are presented in Table 2-1 for screening, pre-admission and admission, and 
Table 2-2 for the on-treatment procedural outline.
When the protocol requires more than one procedure to be completed at the same time point, the 
following will apply to post dose time points:
PK samples should take priority over other procedures scheduled at the same time point. The PK 
sample should be taken at the nominal time point.
As guidance, the preferred order of assessments is:
Vital signs
ECGs
PK blood 
sampling
(nominal time 
point)
Other assessments, eg, 
physical examinations
Predose safety blood samples, electrocardiogram (ECG) and vital sign measurements should be 
taken within 2 hours of study treatment. To ensure PK samples can be collected on time, the ECG 
and vital signs measurements may be obtained ± 15 minutes from the nominal post dose time point. 
Discharge ECG and vital sign measurements will be taken ± 1 hour from the nominal time point. 
Post dose safety blood samples will be taken ± 1 hour from the nominal time point.
See Section 6.3.1 for details of meal timings. 
Other assessments, eg, physical examinations, will be performed within the required time windows 
(ie, any time predose or on the specified day).
Admission and screening procedures can be repeated at the discretion of investigator or 
sub-investigator if there is a concern regarding a participant’s safety or eligibility to participate in 
the clinical trial.
Date: 14 April 2021
12
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 2-1:
Screening and Admission Procedural Outline (CV010-062)
Procedure
Screening
Pre-Admission 
(If Required)
Admission
–1
Notes
Eligibility Assessments
Informed Consent
X
A participant is considered enrolled only when a protocol-specific 
informed consent is signed. Must be obtained prior to performing any 
screening procedures. 
Inclusion/Exclusion Criteria
X
X
Admission, update only
Medical History
X
X
All medical history including any toxicities or allergies related to 
previous treatments. Include any COVID-19 history, including 
vaccinations. Refer to Section 6.2. Admission, update only
Demographics
X
Vein Assessment
X
Admission to Clinic
X
Admission will be in the morning of Day 
 of Treatment Period .
Safety Assessments
Physical Examination
X
A full physical examination will be performed at screening. A 
targeted (symptom-driven) physical examination will be performed at 
admission at the discretion of the investigator or sub investigator (see 
Section 9.4.1).
Targeted Physical 
Examination
X
Physical Measurements
X
Includes height, weight and BMI
Vital Signs
X
X
Includes body temperature, respiratory rate, and supine blood pressure 
and heart rate. All measurements should be taken after the participant 
has been supine for at least 5 minutes. See Section 9.4.2
Concomitant Medication Use
X
X
See Section 7.7
Electrocardiogram (ECG)
X
X
Single ECGs should be recorded after the participant has been supine 
for at least 5 minutes. See Section 9.4.3
Laboratory Tests
See Section 9.4.4.
Clinical Laboratory 
Assessments
X
X
Includes blood and urine samples. Participants are required to fast for 
at least 10 hours prior to the collection of blood specimens for clinical 
laboratory tests. Results from the laboratory tests performed on 
Date: 14 April 2021
13
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 2-1:
Screening and Admission Procedural Outline (CV010-062)
Procedure
Screening
Pre-Admission 
(If Required)
Admission
–1
Notes
Day 
 of Treatment Period  must be available and reviewed prior to 
dosing on Day
Follicle-stimulating Hormone
X
Women only, to confirm post-menopausal status. Refer to 
APPENDIX 4.
Urine Pregnancy Test
X
X
Women only.
Serology
X
Includes hepatitis C antibody, hepatitis B surface antigen, and human 
immunodeficiency virus-1 and -2 antibody.
Tests for drugs of abuse
(urine) and alcohol (breath)
X
X
Urine drug screen (including cotinine) and alcohol breath test. See 
Table 9.4.4-1 in Section 9.4.4. These results must also be reviewed
before dosing on Day 
SARS-CoV-2 Antibody
X
Testing for SARS-CoV-2 may be performed based on current infection 
rates and availability of tests. If required, testing will comprise an 
antibody blood test performed at screening (IgG), and an antigen PCR 
test or other antigen test performed at screening, the day before 
admission and discharge from the clinical unit or the day before 
discharge from the clinical unit. The decision on COVID-19 testing and 
the definition of the testing time points will be agreed and documented 
in the ISF.
SARS-CoV-2 Antigen
X
X
Adverse Event Reporting
Monitor for Serious Adverse 
Events
X
X
All SAEs must be collected from the date of participant’s written 
consent until 30 days post discontinuation of dosing or participant’s 
participation in the study if the last scheduled visit occurs at a later 
time
COVID-19: coronavirus disease 2019; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Date: 14 April 2021
14
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 2-2:
On-Treatment Procedural Outline (CV010-062)
Procedure
Treatment Periods 
Treatment Period 
 only
Notes
Clinical Residency
X
X
X
X
X
Participants will be admitted to the clinical unit in the morning of Day 
 of 
Treatment Period , and will remain resident in the clinic until Day  of 
Treatment Period .
Discharge from Clinic
X
Participants will be discharged from the clinic on Day  of Treatment Period .
Discharge from Study
X
Participants will be considered to have been discharged from the study after the 
follow-up phone call (or after the last contact if following up on an AE).
Follow-up Phone Call
X
To ensure the ongoing wellbeing of the participants.
Safety Assessments
Targeted Physical 
Examination
Xc
A targeted (symptom driven) physical examination may be performed at the 
discretion of the investigator or sub-investigator.
Vital Signs
X
X
X
Xc
See notes in screening procedures.
Vital signs will be examined at pre-dose and at 3, 24 and 72 hours post dose.
For Treatment Period  only, vital signs will also be assessed at 1 hour 
15 minutes post dose (ie at the end of infusion).
Electrocardiogram
X
X
X
Xc
See note in screening procedures.
ECGs will be examined at pre-dose and at 3, 24 and 72 hours post dose.
For Treatment Period  only, ECGs will also be assessed at 1 hour 15 minutes 
post dose (ie at the end of infusion).
Concomitant 
Medication Use
X
X
X
X
Xc
X
Adverse Event 
Reporting
Monitor for Serious 
Adverse Events
X
X
X
X
Xc
X
All SAEs must be collected from the date of participant’s written consent until 
30 days post discontinuation of dosing or participant’s participation in the study 
if the last scheduled visit occurs at a later time. 
Date: 14 April 2021
15
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 2-2:
On-Treatment Procedural Outline (CV010-062)
Procedure
Treatment Periods 
Treatment Period 
 only
Notes
Monitor for 
Nonserious Adverse 
Events
X
X
X
X
Xc
X
Nonserious AEs will be recorded from first dose of study treatment until the 
follow-up call.
Laboratory Tests
See Section 9.4.4.
Clinical Laboratory 
Assessments
X
X
Xc
Participants are required to fast for at least 10 hours prior to the collection of 
specimens.
Safety laboratory blood samples will be drawn at predose, 24 hour post dose, 
and safety laboratory blood and urine samples will be collected at discharge
from the clinical unit.
SARS-CoV-2 Antigen
Xc
Testing for SARS-CoV-2 may be performed based on current infection rates and 
availability of tests. If required, testing will comprise an antigen PCR test or 
other antigen test performed at discharge from the clinical unit or the day before 
discharge from the clinical unit. The decision on COVID-19 testing and the 
definition of the testing time points will be agreed and documented in the ISF.
PK Assessments
Serial Blood PK 
Collections
X
X
X
X
X
Refer to PK collection tables in Section 9.5 for timing of collections
Urine PK Collection
X
X
X
X
X
Study intervention
Randomize
X
Participants will be randomized prior to study treatment administration on 
Day , Treatment Period  only
Date: 14 April 2021
16
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 2-2:
On-Treatment Procedural Outline (CV010-062)
Procedure
Treatment Periods 
Treatment Period 
 only
Notes
Administer Study 
intervention
COVID-19: coronavirus disease 2019; IV: intravenous; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a If Day  of a treatment period coincides with the Day  of the previous treatment period, assessments will be documented as 72 hour post dose/predose.
b Not Treatment Period .
c If early withdrawal occurs, the assessments will be the same as for discharge from the clinical unit.
Date: 14 April 2021
17
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
3
INTRODUCTION
Thrombosis is a maladaptive process of vascular occlusion and remains a primary cause of 
cardiovascular morbidity and mortality. The clinical benefits of anticoagulant therapy are well
established for prevention of thrombosis in patients with existing cardiovascular disease (eg, atrial 
fibrillation, deep vein thrombosis and pulmonary embolism). The growing role of anticoagulant 
therapy in the treatment and prevention of thrombosis is continually balanced by the potential 
complications and risks associated with excess bleeding. Although improvements in the 
therapeutic index of anticoagulant therapy have been made with the advent of small molecule 
inhibitors of factor Xa (FXa) or thrombin relative to vitamin K antagonists, dose-dependent 
bleeding continues to be observed.1 Therefore, improving the risk-to-benefit ratio remains a viable 
goal for antithrombotic drug discovery. This requires selecting a molecular target that defines a 
difference between hemostasis and thrombosis.
Factor XI (FXI) is a component of the intrinsic pathway of the coagulation cascade and has been 
postulated to play an important role in maintaining and propagating a formed thrombus. 
Epidemiologic data collected over the past 15 years indicate that, in humans, factor XIa (FXIa)
could play a greater part in thrombosis than in hemostasis. In the Leiden Thrombophilia Study, 
participants with plasma FXI levels in the top 10% of the normal distribution were nearly twice as 
likely to develop venous thromboembolism as the rest of the study population.2 Similarly, human 
participants with severe FXI genetic deficiency have a reduced incidence of deep vein thrombosis.3
Severe FXI deficiency appears to confer protection from ischemic stroke.4 Conversely, higher FXI 
levels were associated with increased risk for ischemic stroke in a study by Yang et al.5 and in the 
Atherosclerosis Risk in Communities (ARIC) study.6 In young women enrolled in the Risk of 
Arterial Thrombosis In relation to Oral (RATIO) contraceptives study, levels of FXIa and FXI 
antigen correlated with arterial thrombosis and stroke risk.7
The attractiveness of FXI as a therapeutic target for anticoagulation is further supported by the 
lack of clinically meaningful bleeding associated with FXI deficiency. Spontaneous bleeding in 
humans with a deficiency in FXI (hemophilia C) is generally rare, and when observed it is usually 
limited to tissues with high fibrinolytic activity (eg, oral cavity, nose, and urinary tract) after direct 
injury or trauma.8In fact, increased tendency for bleeding has only been documented after surgery 
in patients with very severe FXI deficiency (≤ 15 to 20 IU/dL).9 In a 2015 study in patients 
undergoing total knee arthroplasty, a 60% to 80% reduction in circulating FXI induced by an 
antisense oligonucleotide proved more effective than enoxaparin in reducing the risk of  
postoperative venous thromboembolism without an increased risk of bleeding. This study provides 
a proof-of-concept in humans for FXI inhibition.10 Current evidence supports the hypothesis that 
inhibition of FXI is a novel mechanism for systemic anticoagulation with a low risk of clinically 
significant bleeding.
Date: 14 April 2021
18
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
3.1
Background
Milvexian (also known as BMS-986177 or JNJ-70033093) is a small molecule therapeutic agent 
that binds and inhibits FXIa with high affinity and selectivity. Milvexian is being developed as an 
orally administered anticoagulant to prevent and treat atherothrombotic and thromboembolic 
disorders. Depending on the specific situation, milvexian is expected to provide benefit to patients 
as add-on therapy to the current standard of care therapy or, potentially, as a replacement of current 
standard of care.
The Investigator Brochure (IB) for milvexian provides detailed information on the preclinical 
pharmacology, toxicology, metabolism, PK, absorption, distribution, metabolism, elimination, and 
potential for drug-drug interactions of milvexian. The clinical experience to date is summarized 
below, and in addition can be found in the IB.11
3.1.1
Clinical Pharmacology and Safety
As of 07 December 2020, 2211 participants (ie, 513 healthy participants [includes 17 mild and 
moderate hepatic-impaired participants and 16 moderate and severe renal-impaired participants], 
984 participants who underwent elective total knee replacement (TKR) surgery, 39 participants 
with end-stage renal disease undergoing regularly scheduled chronic stable hemodialysis (HD) 
treatment, and 675 participants with acute ischemic stroke or transient ischemic attack within 48 
hours of symptom onset) have been included and exposed to study drug (milvexian, placebo, or 
comparator) in the milvexian clinical program. 
Of the 2211 participants randomized and exposed, 1763 participants received milvexian, of which 
458 participants were exposed to milvexian in the Phase 1 studies and 1305 participants were 
exposed to milvexian in the Phase 2 and 2a studies. One participant
 
was discontinued early due 
. This participant was 
replaced and was not included in the total counts of participants treated (2211).
Date: 14 April 2021
19
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Nonclinical toxicity and clinical studies to date have demonstrated an acceptable safety profile to 
allow continued testing of milvexian in humans.
3.2
Study Rationale
This study is being conducted to evaluate the absolute oral bioavailability of milvexian when 
administered as the spray-dried dispersion (SDD) in capsule formulation and an oral solution 
formulation. Additionally, fed and fasted state bioavailability comparisons of the capsule 
formulation will be conducted, at a clinically relevant dose range.
Milvexian is targeted as a safe and effective oral agent for the treatment and prevention of 
atherothrombotic and thromboembolic disorders associated with a variety of diseases. Information 
on the renal elimination and clarification of the PK at clinically relevant doses are required to take 
into future clinical studies. The study is not testing statistically any formal hypotheses. 
3.2.1
Pharmacokinetics
In the FIH study, after single doses of milvexian ranging from 4 mg to 500 mg in the fasted state, 
milvexian plasma concentrations reached the maximum observed concentration (Cmax) at 3 hours 
post dose in all panels, indicating a similar rate of absorption. Over the 4 mg to 500 mg dose range, 
the geometric mean milvexian Cmax and AUC(0-T) values increased in a greater than dose 
proportional manner, at 139- and 168-fold, respectively, for a 125-fold dose increase; while the 
AUC(INF) increased 102-fold, which was lower than dose proportional.
At the 200 mg and 500 mg doses, the rate of absorption was delayed by 1 hour by food intake,
indicated by a 1-hour shift in median time of maximum observed concentration (Tmax). In 
addition, the mean T1/2 was 1.5 hours shorter following administration with food (9.04 hours vs 
10.5 hours for 200 mg, and 10.7 hours vs 12.2 hours for 500 mg in study CV010001).
The mean total amount of milvexian excreted in the urine over the 0- to 24-hour period in the 
200 mg once daily (QD) panel (fasted and fed) and 300 mg QD panel was low to moderate, with 
Date: 14 April 2021
20
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
values ranging from 6.94% to 17.8% of the dose; it was also low in the 500 mg fasted treatment, 
with a value of 7.09% of the dose excreted in the urine over the 0- to 24-hour period and moderate 
in the 500-mg fed treatment, with a value of 16.3% of the dose excreted in the urine over the 0- to 
24-hour period.
3.2.2
Pharmacodynamics
In the FIH study, administration of a single oral dose or multiple oral doses of milvexian resulted 
in a dose- and concentration-related prolongation of activated partial thromboplastin time (aPTT)
and decreased FXI clotting activity. The magnitude of aPTT prolongation reduced following the 
decline in milvexian plasma concentration. The changes in aPTT are consistent with the proposed 
mechanism of action of milvexian, reflecting a highly selective, direct, and reversible inhibition of 
FXIa by milvexian. Prothrombin time and international normalized ratio (INR) were not impacted 
by the administration of a single dose or multiple doses of milvexian, with a maximal mean percent 
change from baseline of approximately 5%.
3.2.3
Safety and Tolerability
Milvexian was safe and well tolerated in healthy participants at doses up to 500 mg daily for 
14 days and in participants with end-stage renal disease or renal impairment at a single dose up to 
300 mg, and in participants with hepatic impairment at a single dose of 60 mg. 
Date: 14 April 2021
21
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
3.3
Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonably 
anticipated AEs of milvexian may be found in the IB.11
3.3.1
Risk Assessment
Table 3.3.1-1:
Risk Assessment
Potential Risk of Clinical 
Significance
Summary of Data/Rationale for 
Risk
Mitigation Strategy
Study Interventions
Exposure to milvexian
 oral dose of 
 mg 
milvexian (as SDD capsules in the 
fed and fasted state, and as the oral
solution) and a 
 dose of 
mg (as SDD capsule in the fed 
state), will be dosed across 
treatment periods in this study
Milvexian has been shown to be 
safe and well tolerated in healthy 
participants at doses up to 500 mg 
daily for 14 days.
Only healthy participants will be 
enrolled in this study (see 
Sections 6.1 and 6.2).
The overall safety profile of 
milvexian in healthy participants 
supports clinical evaluation of the 
PK profile and safety/tolerability of 
 oral doses of 
 mg and 
mg milvexian in healthy 
participants. Based on available 
data, a low risk of bleeding is 
expected with administration of 
 doses.
Exposure to radiolabeled
intravenous microdose
Participants in this study are 
exposed to ionizing radiation. It is 
believed that any increase in the 
amount of radiation that is received 
above background radiation carries 
a risk of later developing serious 
and possibly fatal conditions
Based on National Radiological 
Protection Board (NRPB) 
publication NRPB-R245, the 
radioactive administrations will 
result in an effective dose of 
<0.1 mSv. In comparison, the UK 
average radiation exposure for an 
individual is about 2.7 mSv (data 
obtained from Public Health 
England [PHE] Ionising Radiation 
Exposure of the UK Population: 
2010 Review) per year and as such 
the radiation risk to participants in 
this study is considered negligible.
Study Procedures
ECG stickers
Stickers on the participants’ chests 
and limbs may cause some local 
irritation and may be uncomfortable 
to remove
Participants will be closely 
monitored to ensure any local 
irritation does not persist
Date: 14 April 2021
22
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 3.3.1-1:
Risk Assessment
Potential Risk of Clinical 
Significance
Summary of Data/Rationale for 
Risk
Mitigation Strategy
Collecting blood samples
Collecting a blood sample from a 
vein may cause pain, swelling, 
bruising, light headedness, fainting, 
and very rarely, clot formation, 
nerve damage and/or infection at 
the site of the needle stick
Participants will be closely 
monitored
Cannulation
During cannulation, more than one 
attempt may be needed to insert the 
cannula in a vein of a participant 
and it is possible that bruising 
and/or inflammation may be 
experienced at the site of 
cannulation
Participants will be closely 
monitored to ensure any local 
irritation/inflammation does not 
persist
3.3.2
COVID-19 Related Risks and Risk Mitigation Measures
The following risks and risk mitigating measures apply to the time in which the study is conducted 
during the coronavirus disease 2019 (COVID-19) pandemic. 
3.3.2.1
IMP Related Risk
Against the background of the COVID-19 pandemic, the potential risk of a participant developing 
COVID-19 has been considered in terms of the risk-benefit evaluation. The mode of action of the 
IMP – as a reversible FXIa inhibitor – has been considered alongside available pre-clinical and 
clinical data (including class effects) and it is considered that a participant would not be at 
increased risk of either becoming infected with severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2; the virus that causes COVID-19) or experiencing a more severe illness. That is, 
the IMP has no known immunomodulatory effect that would confer an increased risk to healthy 
participants enrolled in the study.
3.3.2.2
General COVID-19 Related Risk Mitigation Measures
General risk mitigation against COVID-19 will be implemented in accordance with 
monitoring and prevention control measures.
COVID-19 testing may be performed based on current infection rates and availability of tests. If 
required, testing will comprise an antibody blood test performed at screening, and an antigen 
polymerase chain reaction (PCR) test or other antigen test performed at screening, the day before 
admission and discharge from the clinical unit or the day before discharge from the clinical unit. 
Testing time points may be changed and additional time points may be added throughout the study 
as required. The decision on COVID-19 testing and the definition of the testing time points will 
be agreed and documented in the Investigator Site File (ISF).
The risk mitigation measures, where applicable, will be amended based on emerging government 
guidance.
Date: 14 April 2021
23
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
3.3.2.3
COVID-19 Vaccine-Related Risk
Approved (including health authority conditional marketing authorization) COVID-19 vaccines 
eg killed, inactivated, peptide DNA and RNA vaccines may be permitted before enrollment 
according to the investigator’s discretion and as per local guidance. 
Based on the mechanism of action of the IMP, as a reversible FXIa inhibitor, there is no perceived 
impact on the safety of the study participants or on the study objectives for participants who may 
receive these vaccines (either first or second doses). It is also very unlikely that administration of 
the IP would interfere with COVID-19 vaccination response; however, no specific preclinical or 
clinical investigations have been conducted at this point with milvexian. 
3.3.3
Benefit Assessment
The current study is a Phase 1 study of milvexian in healthy participants. Participants will receive 
no known health benefit from participating in the study beyond that of an assessment of their 
overall status.
3.3.4
Overall Benefit/Risk Conclusion
There is no benefit to the participants from taking part in this study. The development of a product 
for the prevention and treatment of atherothrombotic and thromboembolic disorders could benefit 
patients with diseases associated with atherothrombotic and thromboembolic disorders.
The overall risk benefit balance is therefore considered to be acceptable.
4
OBJECTIVES AND ENDPOINTS
Table 4-1:
Objectives and Endpoints
Objectives
Endpoints
Primary
Primary
•
To assess the absolute oral bioavailability of 
 doses of milvexian administered as: a 
 mg solution (fasted), 
mg SDD capsule 
(fed and fasted) and 
mg SDD capsule (fed 
and fasted), to healthy participants
•
Absolute oral bioavailability (F) for each treatment
Secondary
Secondary
•
To characterize the IV and the oral PK of 
milvexian following 
 administration in 
the fed and fasted states to healthy participants
•
Cmax, Tmax, AUC(0-T), AUC(INF), CLT or CLT/F, 
CLR, Vz or Vz/F, Ae, %UR, T-HALF, for each 
treatment
•
MRT and Vss of [14C]milvexian following an IV dose
•
Frel for each SDD capsule treatment vs oral solution 
formulation
•
Food effect with 
mg and 
 mg SDD capsules based 
on ratios of Cmax, AUC(0-T), and AUC(INF)
•
To assess the safety and tolerability of 
milvexian
following 
 oral and IV 
administration, to healthy participants
•
Occurrence of AEs and SAEs, abnormalities in vital 
sign measurements exceeding pre-defined thresholds, 
findings on ECGs and physical examinations, and 
abnormalities in clinical laboratory tests
Date: 14 April 2021
24
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 4-1:
Objectives and Endpoints
Objectives
Endpoints
CLR: renal clearance; CLT: total clearance; CLT/F: apparent clearance of drug after extravascular administration; 
Frel: relative bioavailability ; IV: intravenous; MRT: mean residence time; T-HALF: half-life; %UR: percent 
urinary recovery; Vss: volume of distribution at steady state; Vz: volume of distribution of terminal phase; Vz/F: 
apparent volume of distribution at terminal phase after extravascular administration.
5
STUDY DESIGN
5.1
Overall Design
•
This is a Phase 1, open-label, partially randomized, 
period crossover study to evaluate the 
absolute bioavailability of milvexian following oral administration of a 
 dose of the oral
solution in conjunction with a 14C microdose given at the Tmax of the oral solution when 
fasted, and crossover 
 doses of SDD capsules at two dose levels in the fed and fasted 
state across  treatment periods in healthy volunteers. The duration of study participation is 
expected to be up to approximately 7 weeks (including screening).
•
Participants will undergo screening evaluations to determine study eligibility within 
 days 
prior to initial administration of study treatment (Day , Treatment Period ). Participants will 
be admitted to the clinical facility on the morning of Day 
 of Treatment Period  and will 
remain in the facility for the entire duration of the dosing treatment periods, including washout. 
•
On Day  of Treatment Period  all participants will be randomized to a treatment sequence, 
with the treatment for Treatment Period  fixed owing to logistical consideration of the 
radiolabeled investigational product.
•
Participants will be randomized to 1 of 4 treatment sequences immediately prior to 
administration of treatment in Treatment Period . A 4-sequence Latin square, will be used; 
the treatment sequences are presented in Table 5.1-1
. Fasted study treatments will be administered following an overnight fast of at least 10 hours 
and fed study treatments will be administered 30 minutes after the start of a high-fat a meal. 
•
On the morning of Day  of Treatment Period  all participants will receive the milvexian
mg oral solution, in the fasted state followed 1 hour later by the IV [14C]milvexian
 μg 
microdose, containing NMT 
 kBq, infused over 15 minutes.
•
On the morning of Day  for Treatment Periods 
, participants will receive milvexian SDD 
capsules, at doses of 
mg and 
mg in the fed and fasted states, in an order according to 
the randomization schedule, with a minimum 72 hour washout between dose administration in 
each treatment period.
•
Participants will be discharged from the clinical unit 72 hours after the final dose of study 
treatment (ie following Treatment Period ).
•
There will be a follow up phone call 5 to 7 days post final dose (ie Treatment Period , Day  
) to ensure the ongoing wellbeing of the participants.
Table 5.1-1:
Treatment Sequences
Sequence number
1
A
B
C
E
D
Date: 14 April 2021
25
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 5.1-1:
Treatment Sequences
Sequence number
2
A
C
D
B
E
3
A
D
E
C
B
4
A
E
B
D
C
A: 
mg milvexian oral solution with 
 μg IV microdose; B: 
mg milvexian SDD fasted; C: 
mg 
milvexian SDD fed; D: 
mg milvexian SDD fasted; E: 
mg milvexian SDD fed. TP: treatment period.
Physical examinations, vital sign measurements, 12-lead electrocardiograms (ECGs), and clinical 
laboratory evaluations will be performed at selected times throughout the dosing interval. 
Participants will be closely monitored for AEs throughout the study. Blood and urine samples will 
be collected for up to 72 hours after study intervention administration for pharmacokinetic (PK) 
analysis. Less than 550 mL of blood will be drawn from each participant during the study.
5.1.1
Data Monitoring Committee and Other Committees
A Data Monitoring Committee or other review committee will not be used in the study.
5.2
Number of Participants
A total of 16 participants will be randomized to ensure at least 13 participants complete the study 
and are evaluable.
Date: 14 April 2021
26
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
5.3
End of Study Definition
The start of the trial is defined as the first participant first visit. 
End of trial is defined as the last participant last visit (ie follow-up phone call or last contact if 
following up on an AE). 
Study completion is defined as the final date on which data for the primary endpoint were or are
expected to be collected, if this is not the same.
A participant is considered to have completed the study if he/she has completed the last procedure 
shown in the schedule of activities.
The EC and MHRA should be notified in writing of the conclusion of the study within 90 days of 
the end of the study, or within 15 days if the study is terminated early, clearly explaining the 
reasons for the termination.
ARSAC and the ARSAC Practitioner will also be notified of the end of trial or early termination 
of the trial in writing within an appropriate timeframe.
5.4
Scientific Rationale for Study Design
The purpose of this study is to assess the absolute oral bioavailability of an SDD formulation of 
milvexian at a clinically relevant dose range, in the fed and fasted states, and to bridge the 
exposures seen using the oral solution.
Randomization will be used for 4 of the 5 regimens to minimize bias in the assignment of 
participants to treatment groups, to increase the likelihood that known and unknown participant
attributes (eg demographic and baseline characteristics) are evenly balanced across treatment 
groups, and to enhance the validity of comparisons across dose groups. The regimen containing 
the radiolabeled intravenous (IV) microdose will not be randomized owing to logistical 
considerations.
The IV microtracer technique is an established methodology for measuring the IV and oral kinetics 
of a drug in the same individuals in a single dosing period. The technique involves concurrent 
administration of a microdose of the drug containing microtracer amounts of 14C with a single oral 
therapeutic dose, which avoids the concerns of dose-dependent kinetics when extrapolating IV PK 
from a microdose, as the systemic exposure is at therapeutic concentrations. Moreover, for this 
reason the IV administration is timed to coincide with the expected Tmax of the oral dose. This 
design enables measurement of 14C-labelled drug in plasma following IV dosing via sensitive 
accelerator mass spectrometry (AMS) techniques, and measurement of the unlabeled parent in the 
plasma by standard high performance liquid chromatography mass spectrometry/mass 
spectrometry (HPLC MS/MS) techniques. Thus, it is possible to obtain the IV PK parameters with 
Date: 14 April 2021
27
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
the associated variability and calculate the absolute bioavailability. In addition, because the IV 
dose administration involves giving a low volume of a low concentration of parent drug, an 
advantage of this approach is that it is much easier to develop an IV formulation for micro dosing, 
than it would be for a higher clinical dose.
Date: 14 April 2021
28
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
6
STUDY POPULATION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.
6.1
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
1) Signed Written Informed Consent
a) Participants must have signed and dated an Independent Ethics Committee (IEC)-approved 
written informed consent form (ICF) in accordance with regulatory, local, and institutional 
guidelines. This must be obtained before the performance of any protocol-related 
procedures.
b) Participants must be willing and able to communicate and complete all study-specific 
procedures and visits.
2) Type of Participant and Target Disease Characteristics
a) Healthy male or female volunteer, as determined by no clinically significant deviation from 
normal in medical history, physical examination, ECGs, and clinical laboratory 
determinations.
b) Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, at screening. BMI = weight 
(kg)/(height [m])2.
3) Age of Participant
Participant must be 18 to 65 years of age, inclusive, at the time of signing the informed consent.
4) Reproductive Status
•
Investigators shall counsel male participants who are sexually active with women of 
childbearing potential (WOCBP) on the importance of pregnancy prevention, the implications 
of an unexpected pregnancy, and the potential of fetal toxicity occurring due to transmission 
of study intervention, present in seminal fluid, to a developing fetus, even if the participant has 
undergone a successful vasectomy or if the partner is pregnant.
•
The investigator shall evaluate the effectiveness of the contraceptive method in relationship to 
the first dose of study intervention.
Date: 14 April 2021
29
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
Local laws and regulations may require the use of alternative and/or additional contraception 
methods.
a) Female Participants: 
•
A female participant is eligible to participate if:
She is a woman not of childbearing potential (WNOCBP), as defined in APPENDIX 
4: WOCBP Definitions and Methods of Contraception.
She has a negative urine pregnancy test at screening and admission.
b) Male Participants:
•
Males who are sexually active with WOCBP must agree to follow instructions for method(s) 
of contraception as defined in APPENDIX 4 and as described below.
i)
Azoospermic males are exempt from contraceptive requirements.
ii) Male participants are required to use a condom during the intervention period and for 
at least 92 days after the last dose of study intervention.
iii) Female partners of males participating in the study should also be advised to use highly 
effective methods of contraception during the study intervention period and for at least 
92 days after the last dose of the male participant’s study intervention.
iv) Male participants with a pregnant or breastfeeding partner must agree to remain 
abstinent from penile-vaginal intercourse or use a male condom during each episode of 
penile penetration during the intervention period and for at least 92 days after the last 
dose of study intervention.
v) Male participants must refrain from donating sperm during the intervention period and 
for at least 92 days after the last dose of study intervention.
vi) Breastfeeding partners should be advised to consult their health care providers about 
using appropriate highly effective contraception during the time the participant is 
required to use condoms.
The following criterion will be reassessed at admission: 2)a).
6.2
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
5) Medical Conditions
a) History of gastrointestinal (GI) disease: gastroesophageal reflux, dyspepsia, protracted 
nausea, chronic diarrhea, upper GI ulcer disease within 6 months, ulcerative colitis, 
regional enteritis, diverticulosis, diverticulitis, or surgery that could affect the absorption 
of study drug
b) History of upper or lower GI bleeding within 6 months, including hemorrhoids with rectal 
bleeding
c) Any gastrointestinal surgery that could affect the absorption of study intervention
d) Clinically relevant head injury within the last 2 years, as judged by the investigator
e) Any intracranial bleeding or history of intracranial bleeding
f)
Intracranial tumor or aneurysm or abdominal aneurysm  
Date: 14 April 2021
30
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
g) Major surgical procedures within 4 weeks prior to dosing) or planned within 2 weeks after 
completion of the study
h) History or evidence of abnormal bleeding or coagulation disorder and/or evidence of 
coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent 
unexplained bruising or thrombus formation, or a history of spontaneous bleeding, such as 
epistaxis, or family history of coagulopathies
i)
History of menorrhagia
j)
Inability or not willing to be venipunctured/cannulated and/or tolerate venous access
k) Any history of drug or alcohol abuse as defined in Diagnostic and Statistical Manual of 
Mental Disorders (5th Edition) (DSM 5), Diagnostic Criteria for Drug and Alcohol Abuse
a) Regular alcohol consumption in males > 21 units per week and females > 14 units per 
week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass 
of wine, depending on type)
b) Current smokers and those who have smoked (or used other nicotine-containing products 
or devices) within the last 12 months. A positive urine cotinine result at screening or 
admission
l)
Any acute or chronic medical illness considered clinically significant by the investigator
m) Donation of blood to a blood bank or in a clinical study (except a screening visit) within 
4 weeks of study enrollment (within 2 weeks for plasma only)
n) Blood transfusion within 4 weeks of study enrollment
o) Evidence of current SARS-CoV-2 infection
p) Suspected or confirmed history of SARS-CoV-2 infection within 12 weeks prior to signing 
consent or people with a history of the infection who have not fully recovered weeks or 
even months after first experiencing symptoms, so called “long COVID”.
q) History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic 
respiratory, neurological or psychiatric disorder, as judged by the investigator
r)
History of cholecystectomy or gall stones
6) Reproductive Status
a) Women who are of childbearing potential. All women must have a negative urine 
pregnancy test at screening and admission
7) Prior/Concomitant Therapy
a) Inability to comply with restrictions and prohibited treatments as listed in Section 7.7: 
Concomitant Therapy
b) Prior exposure to or allergy to milvexian and/or allergy to its excipients (Study CV010020
[QCL118141])
c) Use within 2 weeks prior to dosing of study drug: non-steroidal anti-inflammatory drugs 
(NSAIDs), anticoagulants and any other drug or agent known to increase the risk for 
bleeding
d) Exposure to any investigational drug within 90 days prior to first milvexian administration
e) Participants who are taking, or have taken, any prescribed or over-the-counter drug (other 
than ≤4 g of paracetamol per day on an as-needed basis or hormone replacement therapy 
[HRT]) or herbal remedies in the 14 days before study treatment administration (See 
Date: 14 April 2021
31
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Section 7.7). Exceptions may apply on a case by case basis, if considered not to interfere 
with the objectives of the study, as agreed by the investigator and cleared by the BMS 
Medical Monitor.
8) Physical and Laboratory Test Findings
a) Evidence of organ dysfunction or any clinically significant deviation from normal in 
physical examination, vital signs, ECG, or clinical laboratory determinations beyond what 
is consistent with the target population
b) Any of the following on 12-lead ECG prior to study intervention administration, confirmed 
by repeat:
i)
PR ≥210 msec
ii) QRS ≥120 msec
iii) QT ≥500 msec
iv) QTcF ≥450 msec
c) Positive urine screen for drugs of abuse
d) Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or human 
immunodeficiency virus (HIV)-1 and -2 antibody
e) A confirmed positive alcohol breath test at screening or admission
f)
Any other laboratory or procedure abnormalities that, in the opinion of the investigator, 
might place the participant at unacceptable risk for participation in this study (See Table 
9.4.4-1 for laboratory parameters). Participants with Gilbert’s Syndrome are allowed
9) Allergies and Adverse Drug Reaction
a) History of allergy to FXIa inhibitors or related compounds
b) History of any drug allergy considered clinically significant by the investigator. Hay fever 
is allowed unless it is active
10) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated. (Note: Under certain specific 
circumstances and only in countries where local regulations permit, a person who has been 
imprisoned may be included or permitted to continue as a participant. Strict conditions 
apply, and Bristol Myers Squibb (BMS) approval is required.)
b) Inability to comply with restrictions as listed in Section 6.3: Lifestyle Restrictions
c) Participants who are sponsor or study site employees, or immediate family members of a 
study site or sponsor employee
d) Radiation exposure, including that from the present study, excluding background radiation 
but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 
12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in 
the Ionising Radiation Regulations 2017,12 shall participate in the study
e) Participants who have been administered investigational product (IP) in an ADME study 
in the last 12 months
f)
Failure to satisfy the investigator of fitness to participate for any other reason
Date: 14 April 2021
32
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
participants and that the results of the study can be used. Participants must fully meet all eligibility 
criteria.
The following criteria will be re-assessed at admission: 5)g), b), 5)l), 5)o), 6)a), 7)c), 7)e), 8)b),
8)c), 8)e), 8)f), 9)b), 6)b) and 6)f).
6.3
Lifestyle Restrictions
In addition to the eligibility criteria at screening (Sections 6.1 and 6.2), participants are required 
to adhere to the following restrictions during the study. The lifestyle restrictions listed below are 
not exclusion criteria; if noncompliance occurs, following discussion between the investigator and 
medical monitor, a protocol deviation will be completed and the participant will be allowed to 
participate in the study.
6.3.1
Meals and Dietary Restrictions
11) Eligible participants will be admitted to the clinical facility on the morning of Day 
 of 
Treatment Period  and will fast overnight for a minimum of 10 hours. Participants will be 
confined at the study site through 72 hours (to morning of Day ) post final IP dose in
Treatment Period . Standardized meals will be served throughout the confinement portion of 
the study and should be the same for every treatment period (except for the high-fat meal which 
is only served in 2 of the treatment periods).
1) Participants should fast (nothing to eat or drink except water) for at least 10 hours prior to 
collection of specimens for scheduled clinical laboratory tests. 
12) Fasting Requirements:
a) On the evening prior to dosing the fasted regimens, participants will be provided with a 
light snack and will then be required to fast (nothing to eat or drink except water) from 
10 hours prior to administration of study treatment. Participants must not drink water from 
1 hour before until 1 hour after administration of study treatment except water provided to 
take study treatment. Water may be consumed ad libitum at other times. Decaffeinated 
fluids will be allowed ad libitum from lunch time (approximately 4 hours after study 
treatment administration).
b) On Day  (dosing day), a standard lunch will be served approximately 4 hours post dose. 
A standard evening meal will be served approximately 10 hours post dose, and an evening 
snack at approximately 14 hours post dose. The percentage of food consumed and timing 
of meals will be recorded for all Day  meals. Meals will be provided to participants at 
standardized times on non-dosing days.
13) Fed Dosing: Two regimens will be dosed in the fed state, following a high-fat breakfast.
a) On the evening prior to dosing the fed regimen, participants will be provided with a light 
snack and will fast from all food and drink (except water) for a minimum of 10 hours prior 
to administration of study treatment until the following morning, when they will be 
provided with a high-fat breakfast.
b) Participants must not drink water from 1 hour before until 1 hour after administration of 
study treatment except water provided to take study treatment and fluids given with the 
high-fat meal. Water may be consumed ad libitum from 1 hour after administration of study 
Date: 14 April 2021
33
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
treatment. Decaffeinated fluids will be allowed ad libitum from lunch time (approximately 
4 hours after administration of study treatment).
c) The meal (high fat) should be consumed over a maximum period of 25 minutes, with 
dosing occurring 30 minutes after the start of the meal. Participants should be encouraged 
to eat their meal evenly over the 25-minute period. It is acknowledged that some 
participants will take less time to eat, but dosing should still occur 30 minutes after the start 
of the meal. Participants must consume 100% of the predose meal in order to be eligible 
for dosing.
14) The acceptable deviation for the predose meal from the nominal dosing time point is:
15) The meal will be administered ± 5 minutes of the nominal time point 
a) A standardized lunch will be provided at approximately 4 hours post dose, a standardized 
evening meal at approximately 10 hours post dose and a standardized evening snack at 
approximately 14 hours post dose. The percentage of food consumed and timing of meals 
will be recorded for all Day  meals. Meals will be provided to participants at standardized 
times on non-dosing days.
6.3.2
Other Dietary Restrictions
•
Participants are not permitted to consume any nutrients known to modulate cytochrome p-450 
(CYP) enzyme activity (eg, grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville 
[blood] orange products) from 48 hours prior to admission until after discharge from the 
clinical unit.
•
Participants are not permitted to consume food containing poppy seeds for 48 hours prior to 
screening and for 48 hours prior to admission until after discharge from the clinical unit.
6.3.3
Caffeine, Alcohol and Tobacco
•
During the study, participants will abstain from ingesting caffeine- or xanthine-containing 
products (eg, coffee, tea, cola drinks, and chocolate) for 24 hours prior to admission until 
discharge from the study.
•
During the study, participants will abstain from alcohol for 24 hours prior to screening and the 
24 hours prior to admission until discharge from the study.
•
Participants are not permitted to smoke or use electronic cigarettes or any nicotine-containing 
products within 12 months prior to screening until discharge from the study.
6.3.4
Activity
•
Participants are to refrain from strenuous exercise and contact sports from at least 72 hours 
before the screening visit and then from 72 hours prior to admission until discharge from the 
study.
•
Must not donate blood or plasma (outside of this study), within 4 weeks of study enrollment 
throughout the study duration, and for at least 90 days following last dose of study medication
Date: 14 April 2021
34
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
6.4
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but who 
are not subsequently randomized in the study/included in the analysis population. 
A minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, as applicable, and to respond to queries from regulatory authorities. 
Minimal information includes date of consent, demography, screen failure details, eligibility 
criteria, and any serious AEs.
6.4.1
Retesting During Screening or Lead-in Period
Participant Re-enrollment: This study does not permit the re-enrollment of a participant who has 
discontinued the study as a pretreatment failure.
Retesting of laboratory parameters and/or other assessments within any single Screening will be 
permitted (in addition to any parameters that require a confirmatory value).
The most current result prior to randomization is the value by which study inclusion will be 
assessed, because it represents the participant’s most current clinical state.
Laboratory parameters and/or assessments that are included in Table 2-1, Screening Procedural 
Outline, may be repeated in an effort to find all possible well-qualified participants. Consultation 
with the Medical Monitor may be needed to identify whether repeat testing of any particular 
parameter is clinically relevant.
6.4.2
Activity
•
Participants are to refrain from strenuous exercise and contact sports from at least 72 hours
before the screening visit and then from 72 hours prior to admission until discharge from the 
study.
•
Must not donate blood or plasma (outside of this study), from screening throughout the study 
duration, and for at least 90 days following last dose of study medication
7
STUDY INTERVENTIONS AND CONCOMITANT THERAPY
Study intervention is defined as any investigational intervention(s), marketed product(s), placebo,
procedure(s) or medical device intended to be administered to a study participant according to the 
study protocol.
Study intervention includes IP as indicated in Table 7.1-1.
An IP, also known as investigational medicinal product (IMP) in some regions, is defined a 
pharmaceutical form of an active substance or placebo being tested or used as a reference in a 
clinical study, including products already with a marketing authorization but used or assembled 
(formulated or packaged) differently from the authorized form, or used for an unauthorized 
indication, or when used to gain further information about the authorized form.
Date: 14 April 2021
35
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as IPs.
7.1
Study Interventions Administered
The selection and timing of dose for each participant is as follows:
Table 7.1-1:
Study Interventions
Intervention 
Name
BMS-986177 oral solution
mg
BMS-986177 SDD 
capsules, 
mg
[14C]BMS-986177 Solution for 
Infusion 
μg/mL (NMT 
kBq/ mL)
Dose Formulation
Solution
SDD Capsules
Solution for IV infusion
Unit Dose 
Strength(s)
mg/mL
mg
μg/mL
Dosage Level(s)
mg 
 dose
mg 
 dose
AND
mg 
 dose (as 
×
mg capsules)
μg 
 dose
Route of 
Administration
Oral, fasted
Oral, fasted AND fed 
IV infusion, fasted
Sourcing
Prepared by the trial site
Provided centrally by the 
Sponsor
Prepared by the trial site
Packaging and 
Labeling
The oral solution  will be 
provided in bulk 
container. Each bulk 
container will be labeled 
as required per country 
requirement.
Study intervention will be 
provided in a bottle. Each 
bottle will be labeled as 
required per country 
requirement
Study intervention will be 
provided in a bulk container. 
Each bulk container will be 
labeled as required per country 
requirement
In the morning of Treatment Period , Day , after fasting for at least 10 hours, each participant 
will receive a 
 oral dose of milvexian oral solution, which will be followed by appropriate 
rinses and additional water, for a total volume of 240 mL. The time of dose administration will be 
called “0” hour. At 1 hour post dose (approximately Tmax), participants will receive an IV 
microdose of [14C]milvexian solution for infusion over 15 minutes. 
For IV dosing only: the IV dose will be infused over approximately 15 minutes. This infusion will 
be in the opposite arm being used for PK sampling.
To assess tolerability of the IV administration, the first participant will be dosed at least 30 minutes
prior to dosing the second participant. All subsequent dosing of the IV formulation will be 
staggered by at least 15 minutes. To allow for potential interruptions and pump variations, up to a 
20% difference in duration of the infusion will not be considered a protocol deviation provided the 
full planned dosed is administered as these minor discrepancies should not have a significant 
impact on the overall study objectives. 
The planned infusion time will be 15 minutes; the actual infusion start and stop time will be 
recorded in the source. 
Date: 14 April 2021
36
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
The infusion will finish within ± 3 minutes of the nominal time point
For Treatment Periods 
, in the morning on Day , after fasting for at least 10 hours or 
following a standardized high-fat meal, each participant will receive a 
 oral dose of milvexian
as SDD capsule(s).
At the time of dosing, 240 mL of water will be administered to the participant along with his/her 
oral dose of study intervention. The time of dose administration will be called “0” hour.
Restrictions related to food and fluid intake are described in Section 6.3.
7.2
Method of Study Intervention Assignment
Enrolled participants, including those not dosed, will be assigned sequential participant numbers 
starting with 00001 (eg, 00001, 00002, 00003...). Those enrolled participants meeting inclusion 
and not meeting exclusion criteria will be eligible to be randomized. Randomization numbers will 
be assigned prior to dosing in Treatment Period . The allocation for Treatment Period
 will be 
fixed with all participants to receive the 
 mg oral solution and the 
 μg microdose in 
Treatment Period . 
Participants will not be replaced if they are discontinued from the study secondary to an AE unless 
the AE can be determined to be unrelated to treatment. If a participant is replaced after dosing,
then the replacement participant will be assigned the original participant’s number plus 100. The 
replacement participant will be assigned to the same treatment sequence and will receive all the 
same treatments as the participant being replaced, but a new randomization number will be 
assigned to him/her. For example, Participant 00004 would be replaced by Participant 00104.
Up to 4 replacement participants may be enrolled into the study. The maximum number of 
participants that may be dosed is 20, including any replacements.
7.3
Blinding
This is a randomized open-label study. It has been determined that blinding is not required to meet 
study objectives. Blinding procedures are not applicable and access to treatment assignment 
information is unrestricted.
7.4
Dosage Modification
Not applicable for this Phase 1 study.
7.5
Preparation/Handling/Storage/Accountability
The IP must be stored in a secure area according to local regulations. It is the responsibility of the 
investigator, or designee where permitted, to ensure that IP is only dispensed to study participants. 
The IP must be dispensed only from official study sites by authorized personnel according to local 
regulations.
The product storage manager should ensure that the study intervention is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by BMS. If 
Date: 14 April 2021
37
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
concerns regarding the quality or appearance of the study intervention arise, the study intervention
should not be dispensed, and BMS should be contacted immediately.
Study intervention not supplied by BMS will be stored in accordance with the package insert.
IP documentation (whether supplied by BMS or not) must be maintained that includes all processes 
required to ensure the drug is accurately administered. This includes documentation of drug 
storage, administration and, as applicable, storage temperatures, reconstitution, and use of required 
processes (eg, required diluents, administration sets).
•
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported 
and resolved before use of the study intervention.
•
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).
•
Further guidance and information for the final disposition of unused study interventions are 
provided in the APPENDIX 2.
Storage facilities for controlled substances must be securely locked and substantially constructed, 
with restricted access to prevent theft or diversion, as applicable by local regulations.
7.6
Treatment Compliance
The date and time of each dose administered in the clinic will be recorded in the source documents 
and recorded in the electronic case report form (eCRF). The dose of study intervention and study 
participant identification will be confirmed at the time of dosing by a member of the study site 
staff other than the person administering the study intervention. 
Study intervention will be administered in the clinical facility. After administration of milvexian, 
an examination of the oral cavity is required to verify that a participant has swallowed the
capsule/solution. When multiple capsules are administered as part of a 
 dose, the mouth 
check should be performed after the final capsule has been taken. The participant should drink the 
entire aliquot of water given to swallow the capsules. 
The IV microdose will be administered by trained staff to ensure dosing compliance.
7.7
Concomitant Therapy
7.7.1
Prohibited and/or Restricted Treatments
Prohibited and/or restricted medications taken prior to study intervention administration in the 
study are described below. Medications taken within 4 weeks prior to study intervention 
administration must be recorded on the CRF. Any past vaccinations for SARS-CoV-2 should also 
be recorded on the CRF.
•
Prior exposure to milvexian.
•
Exposure to any investigational drug or placebo within 90 days of study intervention
administration. 
Date: 14 April 2021
38
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
Exposure to IP in an ADME study in the previous 12 months
•
Use of any prescription drugs or over-the-counter medications within 14 days prior to study 
intervention administration, except those medications cleared by the investigator and the BMS 
Medical Monitor.
•
Use of any other drugs, including over-the-counter medications drug (other than 4 g of 
paracetamol per day on an as needed basis or HRT) and herbal remedies, within 14 days prior 
to study intervention administration, except those medications cleared by the investigator and 
the BMS Medical Monitor.
No concomitant medications (prescription, over-the-counter, or herbal) are to be administered 
during study unless they are prescribed for treatment of specific clinical events. Any concomitant 
therapies must be recorded on the CRF.
Approved (including health authority conditional marketing authorization) COVID-19 vaccines, 
eg killed, inactivated, peptide, DNA and RNA vaccines, may be permitted before enrollment 
according to the investigator’s discretion and as per local guidance
7.8
Continued Access to Study Intervention After the End of the Study
At the end of the study, BMS will not continue to provide BMS-supplied study intervention to 
participants as this is a healthy volunteer study.
8
DISCONTINUATION CRITERIA
8.1
Discontinuation From Study Intervention
Participants MUST discontinue IP for any of the following reasons:
•
Participant’s request to stop study intervention. Participants who request to discontinue study 
intervention will remain in the study and must continue to be followed for protocol-specified 
follow-up procedures. The only exception to this is when a participant specifically withdraws 
consent for any further contact with him/her or persons previously authorized by the participant 
to provide this information
•
Any clinical AE, laboratory abnormality, or intercurrent illness which, in the opinion of the 
investigator, indicates that continued participation in the study is not in the best interest of the 
participant
•
Termination of the study by BMS
•
Loss of ability to freely provide consent through imprisonment or involuntarily incarceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness. (Note: Under 
specific circumstances and only in countries where local regulations permit, a participant who 
has been imprisoned may be permitted to continue as a participant. Strict conditions apply, and 
BMS approval is required.)
•
Significant noncompliance with protocol (eg, procedures, assessments, medications). The 
investigator should discuss such issues with the Medical Monitor.
•
Pregnancy
•
Any current evidence of SARS-CoV-2 infection
•
Overt bleeding producing a hemoglobin decrease ≥2 g/dL in 24 hours
Date: 14 April 2021
39
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
Any overt bleeding deemed by the investigator to necessitate discontinuation of study 
medication
•
aPTT values 5× Admission value, confirmed by repeat evaluation and if any bleeding is 
detected
•
alanine aminotransferase (ALT) > 3 × ULN (confirmed following a repeat ALT blood test)
•
QTc interval of > 500 msec or increase in QTc interval of > 60 msec from baseline (confirmed 
by repeat ECG)
•
Bleeding that persists despite application of pressure for at least 15 minutes or cold compresses
•
Need for treatment with a strong CYP3A4/P-gp inhibitor or any CYP3A4/P-gp inducer
•
At the discretion of the investigator for any other reason
Refer to the Schedule of Activities for data to be collected at the time of treatment discontinuation 
and follow-up and for any further evaluations that can be completed.
All participants who discontinue study intervention should comply with protocol-specified 
discharge and follow-up procedures as outlined in Section 2. The only exception to this 
requirement is when a participant withdraws consent for all study procedures, including post
treatment study follow-up, or loses the ability to consent freely (eg, is imprisoned or involuntarily 
incarcerated for the treatment of either a psychiatric or physical illness).
If study intervention is discontinued prior to the participant’s completion of the study, the reason 
for the discontinuation must be documented in the participant’s medical records per local 
regulatory requirements in each region/country and entered on the appropriate CRF page.
8.1.1
Stopping Criteria
The study will be halted, and the risk to other participants evaluated if any of the following criteria 
are met:
•
A serious adverse reaction (ie, a SAE considered at least possibly related to the IP 
administration) in 1 participant.
•
Severe nonserious adverse reactions (ie, severe nonserious AEs considered as, at least possibly 
related to the IP administration) in 2 participants in the same cohort, independent of within or 
not within the same system organ class.
Relatedness to IP will be determined by the investigator.
If the study is halted, a temporary halt will be submitted to the Medicines and Healthcare products 
Regulatory Agency (MHRA) and ethics committee (EC) in the form of a substantial amendment. 
The study may be resumed or terminated; however, it will not be resumed until a further substantial 
amendment to resume the study is submitted and approved by MHRA and EC.
The ARSAC Practitioner will also be informed of the temporary halt.
Date: 14 April 2021
40
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
8.1.2
Study Termination
After the start of protocol activities but prior to the commencement of dosing, the study may be 
terminated by the sponsor and investigator without consultation with the MHRA, EC, ARSAC 
practitioner or ARSAC. Notification of early termination must be provided to the MHRA and EC 
immediately and at the latest within 15 days after the study is terminated, clearly explaining the 
reasons. A description of any follow-up measures taken for safety reasons if applicable, will also 
be provided. The ARSAC Practitioner and ARSAC will also be notified within an appropriate 
timeframe.
If the study is abandoned prior to commencement of any protocol activities, the investigator or 
sponsor must notify the EC, MHRA, ARSAC practitioner and ARSAC (if ARSAC research 
application has been submitted or approved) in writing outlining the reasons for abandonment of 
the trial.
Once exposure to dosing has begun, the study will be completed as planned unless the following 
criteria are satisfied that require a temporary halt or early termination of the study: 
•
The occurrence of serious or severe AEs, as defined in APPENDIX 3, if considered to be 
related to the IP, as defined in APPENDIX 3.
•
New information regarding the safety of the IP that indicates a change in the risk/benefit profile 
for the compound, such that the risk/benefit is no longer acceptable for participants 
participating in the study.
•
Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary study objectives or compromises participant safety.
If any of the above occurs, the study will be terminated if careful review of the overall risk/benefit 
analysis described in Section 3.3 demonstrates that the assumptions have changed and that the 
overall balance is no longer acceptable. In these circumstances, termination can only take place 
with the agreement of the investigator and sponsor. The MHRA, EC, ARSAC practitioner and 
ARSAC will be informed of study termination.
If it becomes necessary to consider termination of the study after dosing has begun, dosing may 
be suspended pending discussion between the investigator, sponsor and ARSAC practitioner 
(where discussion is related to administration of radiation). Dosing will be stopped immediately 
on safety grounds.
The study may be terminated or suspended at the request of the MHRA or EC.
8.1.3
Post-study Intervention Study Follow-up
Participants who discontinue study intervention may continue to be followed (also see 
Section 8.1).
8.2
Discontinuation From the Study
Participants who request to discontinue study intervention will remain in the study and must 
continue to be followed for protocol-specified follow-up procedures. The only exception to this is 
Date: 14 April 2021
41
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
when a participant specifically withdraws consent for any further contact with him/her or persons 
previously authorized by participant to provide this information. 
•
Participants should notify the investigator of the decision to withdraw consent from future 
follow-up.
•
The withdrawal of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is from further treatment with study intervention
only or also from study procedures and/or post-treatment study follow-up, and entered on the 
appropriate CRF page.
•
In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly available information should be used to determine vital status only as appropriately 
directed in accordance with local law.
•
If the participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
8.2.1
Individual Discontinuation Criteria
•
A participant may withdraw completely from the study at any time at his/her own request, or 
may be withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons. This is expected to be uncommon. Stopping study 
intervention is not considered withdrawal from the study.
•
At the time of discontinuing from the study, if possible, early termination procedures should 
be conducted, as shown in the Schedule of Activities (Table 2-2). See the Schedule of 
Activities for data to be collected at the time of study discontinuation and follow-up and for 
any further evaluations that need to be completed (Treatment Period , Day  withdrawal
assessments).
•
The participant will be permanently discontinued both from the study intervention and from 
the study at that time.
•
If the participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
8.3
Lost to Follow-up
The following actions must be taken if a participant fails to return to the clinic for a required study 
visit:
•
All reasonable efforts must be made to locate participants to determine and report their ongoing 
status. This includes follow-up with persons authorized by the participant.
•
Lost to follow-up is defined by the inability to reach the participant after a minimum of 
three (3) documented phone calls, faxes, or emails, as well as lack of response by participant
to one (1) registered mail letter. All attempts should be documented in the participant’s medical 
records.
•
If it is determined that the participant has died, the site will use permissible local methods to 
obtain date and cause of death.
Date: 14 April 2021
42
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
If the investigator’s use of third-party representative to assist in the follow-up portion of the 
study has been included in the participant’s informed consent, then the investigator may use a 
Sponsor-retained third-party representative to assist site staff with obtaining the participant’s 
contact information or other public vital status data necessary to complete the follow-up 
portion of the study. 
•
The site staff and representative will consult publicly available sources, such as public health 
registries and databases, in order to obtain updated contact information.
•
If, after all attempts, the participant remains lost to follow-up, then the last known alive date 
as determined by the investigator should be reported and documented in the participant’s 
medical records.
9
STUDY ASSESSMENTS AND PROCEDURES
•
Study procedures and timing are summarized in the Schedule of Activities (Section 2). 
•
Protocol waivers or exemptions are not allowed.
•
All immediate safety concerns must be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
•
Adherence to the study design requirements, including those specified in the Schedule of 
Activities, is essential and required for study conduct.
•
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria before randomization. The investigator will maintain a 
screening log to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.
•
The maximum amount of blood collected from each participant over the duration of the study, 
including any extra assessments that may be required, will not exceed 550 mL.
•
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the
samples.
9.1
Efficacy Assessments
Not applicable to this Phase 1 study.
9.2
Adverse Events
The definitions of an AE or SAE can be found in APPENDIX 3.
AEs will be reported by the participant (or, when appropriate, by a caregiver, or a surrogate). 
The investigator and any qualified designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for following up
on AEs that are serious, considered related to the study intervention or the study, or that caused 
the participant to discontinue before completing the study. 
Refer to APPENDIX 3 for SAE reporting.
Date: 14 April 2021
43
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
9.2.1
Time Period and Frequency for Collecting AE and SAE Information
All SAEs must be collected from the time of signing the consent, including those thought to be 
associated with protocol-specified procedures, and within 30 days following discontinuation of 
dosing. Nonserious AEs will be recorded until the follow up call.
9.2.2
Method of Detecting AEs and SAEs
AEs can be spontaneously reported or elicited during open-ended questioning, examination, or 
evaluation of a participant. Care should be taken not to introduce bias when collecting AEs and/or 
SAEs. Inquiry about specific AEs should be guided by clinical judgement in the context of known 
AEs, when appropriate for the program or protocol.
9.2.3
Follow-up of AEs and SAEs
•
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see APPENDIX 3).
•
Follow-up is also required for nonserious AEs that cause interruption or discontinuation of 
study intervention and for those present at the end of study intervention as appropriate.
•
All identified nonserious AEs must be recorded and described on the nonserious AE page of 
the CRF (paper or electronic). Completion of supplemental CRFs may be requested for AEs 
and/or laboratory abnormalities that are reported/identified during the course of the study.
All SAEs will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or until the participant is lost to follow-up (as defined in Section 8.3).
Further information on follow-up procedures is given in APPENDIX 3.
9.2.4
Regulatory Reporting Requirements for SAEs
•
Prompt notification by the investigator to the sponsor and 
of SAEs is essential so that 
legal obligations and ethical responsibilities toward the safety of participants and the safety of 
a product under clinical investigation are met.
•
An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will file it along with 
the Investigator’s Brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.
The Sponsor or designee must report AEs to regulatory authorities, ethics committees and ARSAC, 
as appropriate, according to local applicable laws and regulations. A SUSAR (suspected, 
unexpected serious adverse reaction) is a subset of AEs that is believed to be related to an IMP 
and is both unexpected (ie the nature or severity is not expected from the information provided in 
the IB) and serious; and must be reported to the appropriate regulatory authorities, EC and 
investigators following local and global guidelines and requirements.
The ARSAC Practitioner will be notified of any SUSAR that is considered related to the exposure 
to radioactivity.
Date: 14 April 2021
44
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
9.2.5
Reporting of COVID-19 Vaccine-Related Adverse Events
AEs considered by the investigator to be related to COVID-19 vaccines will be reported to the 
MHRA via the Yellow Card system.
9.2.6
Pregnancy
Not applicable for WNOCBP - Protocol-required procedures for study discontinuation and 
follow-up must be performed on the participant.
Any pregnancy that occurs in a female participant or a female partner of a male study participant 
should be reported to the Sponsor or designee. In order for the Sponsor or designee to collect any 
pregnancy surveillance information from a female partner, the female partner must sign an ICF for 
disclosure of this information. Information on this pregnancy will be collected on the Pregnancy 
Surveillance Form.
9.2.7
Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE eCRF, as appropriate. Paper forms are only intended as a back-up option when the 
electronic system is not functioning.
•
Any laboratory test result that is clinically significant or meets the definition of an SAE 
•
Any laboratory test result abnormality that required the participant to have study intervention
discontinued or interrupted
•
Any laboratory test result abnormality that required the participant to receive specific 
corrective therapy
It is expected that, wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia vs low hemoglobin value).
9.2.8
Potential Drug-induced Liver Injury
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential drug-induced liver injury (DILI) event. All occurrences 
of potential DILIs meeting the defined criteria must be reported as SAEs (see Section 9.2 and 
APPENDIX 3 for reporting details).
Potential DILI is defined as: 
•
Aminotransferase (ALT or aspartate aminotransferase [AST]) elevation > 3 times upper limit 
of normal (ULN)
AND
•
Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase)
AND
Date: 14 April 2021
45
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.9
Other Safety Considerations
Any significant worsening of conditions noted during interim or final physical examinations, ECG, 
x-ray filming, or any other potential safety assessment required or not required by the protocol 
should also be recorded as a nonserious AE or SAE, as appropriate, and reported accordingly.
9.3
Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product that 
is considered both excessive and medically important. Overdoses that meet the regulatory 
definition of SAE will be reported as an SAE (see APPENDIX 3).
9.4
Safety
Planned time points for all safety assessments are listed in the Schedule of Activities. A physician 
will be responsible for the clinical aspects of the study and will be available at all times during the 
study. In accordance with the current Association of the British Pharmaceutical Industry 
guidelines13, each participant will receive a card stating the telephone number of the investigator 
and the 24/7 contact details of the 
 on-call physician.
9.4.1
Physical Examinations
Refer to Schedule of Activities (Section 2).
Physical examinations may be performed by a physician.
Physical examinations will include general appearance, head, eyes, ears, nose, throat, neck, 
cardiovascular system, lungs, abdominal, extremities, skin, and musculoskeletal system.
If the screening physical examination is performed within 48 hours prior to Treatment Period  
Day , then a single examination may count as both the screening and admission evaluation.
A targeted (symptom-driven) physical examination may be performed the discretion of the 
investigator or sub-investigator, see Section 2.
All identified nonserious AEs must be recorded and described on the nonserious AE page of the 
CRF.
Documentation of who performed the examination is to be recorded in source notes.
9.4.2
Vital signs
Refer to Schedule of Activities (Section 2).
Vital signs will include oral body temperature, respiratory rate, systolic and diastolic blood 
pressure, and heart rate (HR); all measurements should be taken after the participant has been 
supine for at least 5 minutes.
Date: 14 April 2021
46
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
9.4.3
Electrocardiograms
Refer to Schedule of Activities (Section 2).
Single ECG readings should be recorded after the participant has been supine for at least 5 minutes. 
ECG parameters QTcF, QRS, QT interval, PR interval, HR and QRS axis will be collected on the 
CRF.
In the event that multiple procedures are required at a single time point, ECG assessments will be 
collected prior to PK sample collection. In addition, vital signs should be taken prior to ECGs 
when both measurements are scheduled at the same time point, with a 5 minute rest period between 
vital signs assessment and ECG assessment. 
9.4.4
Clinical Safety Laboratory Assessments
A central laboratory will perform the analyses and will provide reference ranges for these tests.
Details on clinical safety laboratory sample collection, labeling, processing, storage, and shipment 
will be provided in the laboratory/procedure manual.
Results of clinical laboratory tests performed on Day 
 of Treatment Period  must be available 
prior to dosing.
The schedule for collection of samples for each assessment is provided in Section 2. Laboratory 
assessments to be conducted during the study are listed in Table 9.4.4-1.
•
Investigators must document their review of each laboratory safety report.
Table 9.4.4-1:
Clinical Laboratory Assessments
Hematology
•
Hemoglobin
•
Hematocrit (PCV)
•
Platelet count 
•
MCH
•
MCHC
•
MCV
•
Red blood cell count
•
Basophils
•
Eosinophils
•
Monocytes
•
Neutrophils
•
WBC Count
•
Lymphocytes
Coagulation
•
PT
•
aPTT
•
INR
Chemistry
•
Aspartate aminotransferase
•
Alanine aminotransferase 
•
Total bilirubin
•
Direct bilirubin (only required if total is >ULN)
•
Alkaline phosphatase (as reflex test if ALT > ULN)
•
Total protein
•
Albumin
•
Sodium
•
Potassium
•
Chloride
•
Calcium
Date: 14 April 2021
47
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 9.4.4-1:
Clinical Laboratory Assessments
•
Gamma-glutamyl transferase (as reflex test if ALT 
> ULN)
•
Lactate dehydrogenase (as reflex test if ALT > 
ULN)
•
Creatinine
•
Blood urea nitrogen 
•
Uric acid 
•
Fasting glucose
•
Magnesium (as reflex test if calcium < lower limit 
of normal or > ULN)
•
Phosphorus (as reflex test if calcium < lower limit 
of normal or > ULN)
•
Creatine kinase
Urinalysis
•
Protein
•
Glucose
•
Blood
•
Leukocytes
•
Specific gravity
•
Microscopic or microbiological examination at the 
discretion of the investigator based on urinalysis 
results
•
Bilirubin
•
Ketones
•
Nitrites
•
Urobilinogen
•
pH
Serology (at screening only)
•
hepatitis C antibody
•
hepatitis B surface antigen
•
HIV-1 and -2 antibody
•
if required: SARS-CoV-2 Antibody 
•
if required: SARS-CoV-2 Antigen
Other Analyses
Test for drugs of abuse (urine)
•
Amphetamines
•
Barbiturates
•
Benzodiazepines
•
Cocaine
•
Marijuana/Cannabis
•
Methadone
•
Methamphetamine/Ecstasy
•
Morphine/Opiates
•
Phencyclidine
•
Tricyclic Antidepressants
•
•
Cotinine
•
Alcohol breath test (screening and admission on 
Day 
of Treatment Period )
•
Follicle stimulating hormone (screening only for 
women only to confirm postmenopausal status)
•
Urine pregnancy test (women only: screening and
admission)
Abbreviations: MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; MCV, mean cell volume; 
PCV, packed cell volume; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WBC, white blood cell.
Date: 14 April 2021
48
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
9.4.5
Physical Measurements
Physical measurements including height, weight and BMI will be performed at screening 
(Section 2).
Measurement of height should be performed with the participant’s shoes removed, pockets 
emptied and no overcoat. The participant’s knees should be straightened, head held erect, and eyes 
forward. Weight must be recorded using a calibrated scale.
BMI is a method of defining normal body weight and excess body fat. Method of BMI calculation 
is as follows:
•
Use actual height and weight
−
To calculate BMI:
♦BMI = weight (kg)/(height [m])2
♦Round to 1 decimal place (if 0.05 or greater, round up)
The BMI calculation is used for assessment for inclusion. All analysis calculations for BMI will 
be derived internally using the weight and height at the specified time point or the most recent 
height measurement (if not applicable).
9.5
Pharmacokinetics
Pharmacokinetics of milvexian and [14C] milvexian, as applicable, will be derived from plasma 
concentration vs time and urinary excretion data. The pharmacokinetic parameters to be assessed 
include:
F
Absolute oral bioavailability (oral versus IV)
Cmax
Maximum observed plasma concentration
Tmax
Time of maximum observed plasma concentration
AUC(0-T)
Area under the plasma concentration-time curve from time zero to time of last quantifiable 
concentration
AUC(INF)
Area under the plasma concentration-time curve from time zero extrapolated to infinity
Ae
Amount of unchanged drug excreted into the urine
%UR
Percent urinary recovery
T-HALF
Terminal plasma half-life
CLT
Total clearance
CLT/F
Apparent clearance of drug after extravascular administration
CLR
Renal clearance
Date: 14 April 2021
49
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Frel
Relative bioavailability based on Cmax, AUC(0-T) and AUC(INF)
MRT
Mean residence time
Vss
Volume of distribution at steady state
Vz
Volume of distribution of terminal phase
Vz/F
Apparent volume of distribution at terminal phase after extravascular administration
Individual participant PK parameter values will be derived by noncompartmental methods by a 
validated PK analysis program. Actual times will be used for the analyses.
Table 9.5-1Table 9.5-2ist the sampling schedules to be followed for the assessment of 
pharmacokinetics in the plasma and urine, respectively.
Table 9.5-1:
Pharmacokinetic Plasma Sampling Schedule for Milvexian 
Treatment Periods
)
Study Day 
of Sample 
Collection
Event
Time
(Relative To Milvexian
Dose/Oral Dose) Hour:Min
Milvexian
Blood Sample (for 
LC-MS/MS analysis)
[14C]Milvexian
Blood Sample (for 
AMS analysis)a
Predose
00:00
X
X
Post dose
00:30
X
Post dose/SOI
01:00b
X
Post dose
01:05a
X
Post dose
01:10a
X
Post dose/EOI
01:15
X
Xc
Post dose
01:20a
X
Post dose
01:30
X
X
Post dose
01:45a
X
Post dose
02:00
X
X
Post dose
03:00
X
X
Post dose
04:00
X
X
Post dose
05:00
X
X
Post dose
06:00
X
X
Post dose
08:00
X
X
Post dose
10:00
X
X
Post dose
12:00
X
X
Post dose
14:00
X
X
Post dose
18:00
X
X
Date: 14 April 2021
50
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 9.5-1:
Pharmacokinetic Plasma Sampling Schedule for Milvexian 
Treatment Periods
)
Study Day 
of Sample 
Collection
Event
Time
(Relative To Milvexian
Dose/Oral Dose) Hour:Min
Milvexian
Blood Sample (for 
LC-MS/MS analysis)
[14C]Milvexian
Blood Sample (for 
AMS analysis)a
Post dose
24:00
X
X
Post dose
36:00
X
X
Post dose
48:00
X
X
Post dose
72:00d
X
X
AMS: accelerator mass spectrometry; EOI: End of infusion; LC-MS/MS: liquid chromatography mass 
spectrometry/mass spectrometry; SOI: Start of infusion
a Treatment Period (IV microdose regimen) only. 
b The SOI blood sample for LC-MS/MS analysis will be taken prior to administration of the microdose.
c This sample should be taken immediately after stopping the IV infusion. If the end of infusion is delayed, the 
collection of this sample should also be delayed.
d Where Day  of a treatment period coincides with the 72 hour time point of the previous treatment period, only a 
single predose/72 hour post dose sample is required.
Table 9.5-2:
Pharmacokinetic Urine Sampling Schedule for Milvexian 
(Treatment Periods 
)
Study Day of 
Sample 
Collection
Event
Time
(Relative To Milvexian Dose/Oral 
Dose) Hour:Min
Milvexian
Urine Sample
(for LC-MS/MS analysis)
Predosea
00:00
X
0 to 6 h
06:00
X
6 to 12 h
12:00
X
12 to 24 h
24:00
X
24 to 36 h
36:00
X
36 to 48 h
48:00
X
48 to 72 h
72:00b
X
a A single urine sample will be taken at predose (or the first void of the day).
b Where Day  of a treatment period coincides with the 72 hour time point of the previous period, only a single 
72 hour post dose collection is required.
All on-treatment timepoints are intended to align with days on which study intervention is 
administered. If it is known that a dose is going to be delayed, then the predose sample for 
milvexian, if appropriate, should be collected just prior to the delayed dose. However, if a predose 
milvexian sample is collected but the dose is subsequently delayed, an additional predose sample 
should not be collected. Blood samples should be drawn from a site other than the infusion site (ie, 
Date: 14 April 2021
51
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
contralateral arm) on days of infusion. If the infusion was interrupted, the interruption details will 
also be documented on the CRF. Further details of the PK blood and urine sample collection, 
labeling, processing, storage, and shipment will be provided in the laboratory/procedure manual.
The plasma samples will be analyzed for milvexian by a validated liquid chromatography mass 
spectrometry/mass spectrometry (LC-MS/MS) assay or by a qualified accelerator mass 
spectrometry (AMS) assay (analyzed according to the PK sampling schedule described in 
Table 9.5-1). Milvexian in urine will be analyzed by a validated LC-MS/MS assay.
Bioanalytical samples designated for assessments from the same collection time point may be used 
interchangeably for analyses, if needed.
9.6
Immunogenicity Assessments
Not applicable.
9.7
Genetics
Not applicable.
9.9
Additional Research
This protocol will not include sample collection and/or residual sample storage for additional 
research.
9.10
Other Assessments
Not applicable.
9.11
Health Economics
Health economics/medical resource utilization and health economics parameters will not be 
evaluated in this study.
10
STATISTICAL CONSIDERATIONS
10.1
Statistical Hypotheses
No prospective hypotheses are being formally evaluated.
10.2
Sample Size Determination 
Sample size determination is based on consideration of the precision of the estimate of the 
geometric mean ratios (GMR) of Cmax and AUCs of milvexian between test and reference 
treatments. With 13 evaluable participants, there will be an 80% probability that the 90% 
confidence interval (CI) of GMR will be within 80% and 125% of the point estimate. The precision 
estimate is based on the assumptions that Cmax and AUCs of milvexian are log-normally 
distributed with intra-subject coefficient of variation (CV) of no greater than 28.3%. 
 
Date: 14 April 2021
52
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
 
A sample size of 16 participants to achieve 13 evaluable participants is considered appropriate to 
meet the objectives of the study.
10.3
Analysis Sets
For the purposes of analysis, the following populations are defined:
Population
Description
Enrolled 
All participants who have agreed to participate in a clinical study following 
completion of the informed consent process
Treated
All participants who received at least 1 dose of study intervention. This 
population will be used for the safety analyses
PK
All randomized participants who receive at least 1 dose of study drug and have 
any available concentration-time data 
Evaluable PK
The Evaluable PK Population includes all participants in the PK Population 
with adequate PK profiles for accurate estimation of PK parameters
10.4
Statistical Analyses
The statistical analysis plan (SAP) will be developed and finalized before database lock and will 
describe the selection of participants to be included in the analyses and procedures for accounting 
for missing, unused, and spurious data. Below is a summary of planned statistical analyses of the 
primary and secondary endpoints.
A description of the participant population will be included in the clinical study report, including 
subgroups of age, gender, race and other study specific populations and demographic 
characteristics. A description of participant disposition will also be included in the clinical study 
report.
10.4.1
Primary Endpoint
Pharmacokinetic results will be listed for the PK Population; descriptive summary statistics will 
use the Evaluable PK Population
Table 10.4.1-1:
Primary Endpoint
Primary Endpoint
Description
Timeframe
Pharmacokinetics – F
Absolute oral bioavailability (F) for 
each treatment will be summarized, 
and descriptive statistics and 90% 
CI for F will be presented
Following 
 oral dose on 
separate occasions and a 
 
oral dose followed by an IV 
injection on a 
 occasion (i.e., 
Day of Period )
Date: 14 April 2021
53
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
10.4.2
Secondary Endpoints
Table 10.4.2-1:
Secondary Endpoints
Secondary Endpoint
Description
Timeframe
Pharmacokinetics – Cmax, Tmax, 
AUC(0-T), AUC(INF), CLT or 
CLT/F, CLR, Vz or Vz/F, Ae, 
%UR, T-HALF, for each treatment
Summary statistics by treatment 
will be tabulated for plasma 
concentrations and PK parameters 
of milvexian and [14C]milvexian, as 
applicable. Geometric means and 
coefficients of variation (CV%) will 
be presented for Cmax, AUC(0-T), 
AUC(INF), CLT or CLT/F, CLR,
Vz or Vz/F, Ae, %UR. Medians 
and ranges will be presented for 
Tmax. Means and standard 
deviations (SDs) will be presented 
for T-HALF.
Following 
 oral dose on 
separate occasions and a 
 
oral dose followed by an IV 
injection on a single occasion (i.e., 
Day  of Period )
Pharmacokinetics – MRT and Vss 
of [14C]milvexian following an IV 
dose
Summary statistics by treatment 
will be tabulated for plasma 
concentrations and PK parameters 
of 14C]milvexian. Geometric means
and coefficients of variation (CV%) 
will be presented for MRT and Vss.
Following 
 oral dose on 
separate occasions and a 
 
oral dose followed by an IV 
injection on a 
 occasion (i.e., 
Day  of Period )
Pharmacokinetics – Frel for each 
SDD capsule treatment vs oral 
solution formulation
Point estimates and 90% CI for the 
ratio of geometric means for Cmax, 
AUC(0-T) and AUC(INF) will be 
constructed for the comparison of:
•
each 
milvexian
capsule 
treatment 
separately 
versus 
mg oral solution
A linear mixed-effect model will be 
used on log transformed data with 
treatment and period as fixed 
effects, and measurements within 
each participant as repeated 
measures.
Following 
 oral dose on 
separate occasions and a 
 
oral dose followed by an IV 
injection on a 
 occasion (i.e., 
Day  of Period )
Pharmacokinetics – Food effect 
with 
mg and 
 mg SDD
capsules based on ratios of Cmax, 
AUC(0-T), and AUC(INF)
Point estimates and 90% CI for the 
ratio of geometric means for Cmax, 
AUC(0-T) and AUC(INF) will be 
constructed for the comparison of:
•
 mg SDD fed versus 
 mg 
SDD fasted 
•
 mg SDD fed versus 
 mg 
SDD fasted
A linear mixed-effect model will be 
used on log transformed data with 
treatment and period as fixed 
effects, and measurements within 
each subject as repeated measures. 
Following 
 oral dose on 
separate occasions and a 
 
oral dose followed by an IV 
injection on a 
 occasion (i.e., 
Day  of Period )
Date: 14 April 2021
54
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Table 10.4.2-1:
Secondary Endpoints
Secondary Endpoint
Description
Timeframe
Safety – Occurrence of AEs and 
SAEs, abnormalities in vital sign 
measurements exceeding 
pre-defined thresholds, findings on 
ECGs and physical examinations, 
and abnormalities in clinical 
laboratory tests
All recorded SAEs and AEs will be 
listed and tabulated by system 
organ class, preferred term and 
treatment. Adverse events leading 
to discontinuation will be listed. All 
nonserious AEs reported up to the 
follow up call will be included in -
the AE summary tables.
Any abnormal physical 
examination findings will be listed.
Vital signs and clinical laboratory 
test results will be listed. The 
frequency of marked abnormalities 
in clinical laboratory test results 
will also be tabulated by treatment.
ECG readings will be evaluated by 
the Investigator and abnormalities, 
if present, will be listed.
Following 
 oral dose on 
separate occasions and a 
 
oral dose followed by an IV 
injection on a 
 occasion (i.e., 
Day  of Period )
10.4.3
Exploratory Endpoint(s)
Not applicable.
10.4.4
Other Safety Analysis
Not applicable.
10.4.5
Other Analyses 
Not applicable.
10.5
Interim Analyses 
Not applicable.
Date: 14 April 2021
55
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
11
REFERENCES
1
Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin 
compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). 
Am J Cardiol. 2007;100:1419-1426.
2
Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk 
factor for venous thrombosis. N Engl J Med. 2000;342 (10):696-701.
3
Salomon O, Steinberg DM, Sucker M et al. Patients with severe factor XI deficiency have a 
reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105(2):269-273
4
Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in 
patients with severe factor XI deficiency. Blood. 2008;111(8):4113-4117
5
Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated 
with an increased odds ratio for cerebrovascular events. Am J Clin Pathol. 2006;126(3):411-
415
6
Suri MF, Yamagishi K, Aleksic N, et al. Novel hemostatic factor levels and risk of ischemic 
stroke; the Atherosclerosis Risk in Communities (ARIC) study. Cerebrovasc Dis. 2010;29:497 
502
7
Siegerink B, Govers-Riemslag JW, Rosendaal FR, et al. Intrinsic coagulation activation and 
the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis 
in relation to Oral contraceptives (RATIO) case-control study. Circ. 2010;122:1854-1861
8
Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost. 2009;7(1):84-87
9
Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia. 2008;14(6):1183-1189
10 Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of 
venous thrombosis. N Engl J Med. 2015; 372(3): 232-240
11 Milvexian Investigator’s Brochure, Version 7; Janssen Research & Development, LLC/Bristol 
Myers Squibb Company, 29 January 2021, Document Control No. 
.
12 Health and Safety. Ionising Radiation (Medical Exposure) Regulations 2017. Statutory 
Instrument 2017 No. 1322
13 Guidelines for Phase I Clinical Trials. Association of the British Pharmaceutical Industry 
Guidelines. London, UK; 2018 Edition (publication date 29 May 2018)
14 Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed 
radioactive sources. Administration of Radioactive Substances Advisory Committee. February 
2021.
Date: 14 April 2021
56
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
12
APPENDICES
Date: 14 April 2021
57
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
APPENDIX 1
ABBREVIATIONS AND TRADEMARKS
Term
Definition
ADME
absorption, distribution, metabolism and excretion
AE
adverse event
Ae
Amount of unchanged drug excreted into the urine
ALT
alanine aminotransferase
AMS
accelerator mass spectrometry
aPTT
activated partial thromboplastin time
ARSAC
Administration of Radioactive Substances Advisory Committee
AUC
area under the concentration-time curve
AUC(INF)
area under the concentration-time curve from time zero extrapolated to 
infinity
AUC(0-T)
Area under the plasma concentration-time curve from time zero to time 
of last quantifiable concentration
BMI
body mass index
BMS
Bristol Myers Squibb
CI
confidence interval
CLR
renal clearance
CLT
total clearance
CLT/F
apparent clearance of drug after extravascular administration
Cmax
maximum observed plasma concentration
COVID-19
coronavirus disease 2019
CV
coefficient of variation
CYP
cytochrome P450
DILI
drug-induced liver injury
ECG
electrocardiogram
eCRF
electronic Case Report Form
F
absolute oral bioavailability (oral versus IV)
FIH
first-in-human
FSH
follicle-stimulating hormone
Frel
Relative bioavailability
FXa
factor Xa
Date: 14 April 2021
58
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Term
Definition
FXI
factor XI
FX1a
factor XIa
GI
gastrointestinal
GMR
geometric mean ratios
HIV
human immunodeficiency virus
HR
heart rate
HRT
hormone replacement therapy
IB
Investigator’s Brochure
IP
Investigational Product
INR
international normalized ratio
IV
intravenous
MRT
Mean residence time
N/A
not applicable
NMT
not more than
PK
pharmacokinetic
QD
quaque die, once daily
SAE
serious adverse event
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
SDD
spray-dried dispersion
T-HALF
Terminal plasma half-life
Tmax
time of maximum observed plasma concentration
%UR
percent urinary recovery
Vss
Volume of distribution at steady state
Vz
volume of distribution of terminal phase
Vz/F
Apparent volume of distribution at terminal phase after extravascular 
administration
WNOCBP
women not of childbearing potential
WOCBP
women of childbearing potential
Date: 14 April 2021
59
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
APPENDIX 2
STUDY GOVERNANCE CONSIDERATIONS
The terms “participant” and “subject” refer to a person who has consented to participate in the 
clinical research study. Typically, the term “participant” is used in the protocol and the term 
“subject” is used in the Case Report Form (CRF).
REGULATORY AND ETHICAL CONSIDERATIONS
This study will be conducted in accordance with:
•
Consensus ethical principles derived from international guidelines, including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines
•
Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines
•
Applicable laws, regulations, and requirements
The study will be conducted in compliance with the protocol. The protocol, any 
revisions/amendments, and the participant informed consent form (ICF)
will receive 
approval/favorable 
opinion 
by 
Institutional 
Review 
Board/Independent 
Ethics 
Committee (IRB/IEC), and regulatory authorities according to applicable regulations prior to 
initiation of the study.
All potential serious breaches must be reported to the Sponsor or designee immediately. A 
potential serious breach is defined as a Quality Issue (eg, protocol deviation) that is likely to affect, 
to a significant degree, one or more of the following: (1) the rights, physical safety or mental 
integrity of one or more participants; (2) the scientific value of the clinical trial (eg, reliability and 
robustness of generated data). Items (1) or (2) can be associated with either GCP regulation(s) or 
trial protocol(s).
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, Investigator’s Brochure, product labeling information, ICF, 
participant recruitment materials (eg, advertisements), and any other written information to be 
provided to participants.
The investigator, Sponsor, or designee should provide the IRB/IEC with reports, updates, and other 
information (eg, expedited safety reports, amendments, administrative letters) annually, or more 
frequently, in accordance with regulatory requirements or institution procedures.
The investigator is responsible for providing oversight of the conduct of the study at the site and 
adherence to requirements of the following where applicable:
Date: 14 April 2021
60
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
ICH guidelines, 
•
United States Code of Federal Regulations, Title 21, Part 50 (21CFR50)
•
European Union Directive 2001/20/EC; or
•
European Regulation 536/2014 for clinical studies (if applicable), 
•
European Medical Device Regulation 2017/745 for clinical device research (if applicable),
•
the IRB/IEC
•
and all other applicable local regulations.
ADMINISTRATION OF RADIATION
 will be the Principal Investigator and the ARSAC practitioner for this study, which 
includes the administration of radiation at 
. Administration will be conducted in 
accordance with 
current ARSAC practitioner license and 
current ARSAC 
Employer license. Additionally a research application will be submitted to ARSAC to obtain 
approval for the conduct of the study before dosing.
Dosimetry will be calculated in accordance with the current approved ARSAC Employer License
Application for 
 and the current Practitioner License for 
.
The protocol will be reviewed and the final version will be approved by the ARSAC practitioner 
.
Any amendments relating to the administration of radioactive substances will be reviewed by the 
ARSAC practitioner prior to submission to ARSAC as required by the current ARSAC Notes for 
Guidance.14 The ARSAC practitioner will also be notified of any substantial amendments to the 
PIS and ICF and/or protocol.
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any substantial deviation or change to the protocol without 
prior review and documented approval/favorable opinion of an amendment from the IRB/IEC 
(and, if applicable, also by the local Health Authority and ARSAC), except where necessary to 
eliminate an immediate hazard(s) to study participants. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opinion(s), the deviation or change will be submitted as soon 
as possible to:
•
IRB/IEC
•
Regulatory authority(ies), if applicable by local regulations (per national requirements)
Documentation of approval/favorable opinion signed by the chairperson or designee of the 
IRB(s)/IEC(s) and, if applicable, also by the local Health Authority, must be sent to Bristol Myers
Squibb (BMS).
Date: 14 April 2021
61
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
If an amendment substantially alters the study design or increases the potential risk to the 
participant: (1) the ICF must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from participants 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new participants prior to enrollment.
FINANCIAL DISCLOSURE
Investigators and sub-investigators will provide the Sponsor with sufficient, accurate financial 
information, in accordance with regulations, to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate Health Authorities. Investigators 
are responsible for providing information on financial interests during the course of the study and 
for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that participants are clearly and fully informed about the purpose, 
potential risks, and other critical issues regarding clinical studies in which they volunteer to 
participate. 
The Sponsor or designee will provide the investigator with an appropriate sample ICF, which will 
include all elements required by the ICH GCP, and applicable regulatory requirements. The sample 
ICF will adhere to the ethical principles that have their origin in the Declaration of Helsinki.
The investigator or his/her representative must:
•
Obtain IRB/IEC written approval/favorable opinion of the written ICF and any other 
information to be provided to the participant prior to the beginning of the study and after any 
revisions are completed for new information.
•
Provide a copy of the ICF and written information about the study in the language in which 
the participant is proficient prior to clinical study participation. The language must be 
nontechnical and easily understood. 
•
Explain the nature of the study to the participant and answer all questions regarding the study.
•
Inform participant that his/her participation is voluntary. Participant will be required to sign a 
statement of informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, 
where applicable, and the IRB/IEC or study center.
•
Allow time necessary for participant to inquire about the details of the study.
Obtain an ICF signed and personally dated by participant and by the person who conducted the 
informed consent discussion. 
•
Include a statement in participant’s medical record that written informed consent was obtained 
before participant was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.
•
Re-consent participant to the most current version of the ICF(s) during his/her participation in 
the study, as applicable.
Date: 14 April 2021
62
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Revise the ICF whenever important new information becomes available that is relevant to the 
participant’s consent. The investigator, or a person designated by the investigator, should fully 
inform the participant of all pertinent aspects of the study and of any new information relevant to 
the participant’s willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify participants must be protected, respecting the 
privacy and confidentiality rules applicable to regulatory requirements, the participant’s signed 
ICF, and, in the US, the participant’s signed HIPAA Authorization.
The ICF must also include a statement that BMS and local and foreign regulatory authorities have 
direct access to participant records. 
SOURCE DOCUMENTS
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the electronic CRF (eCRF) that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be explained. 
•
The investigator may need to request previous medical records or transfer records, depending 
on the study. Also, current medical records must be available.
•
Definitions of what constitutes source data can be found in the Source Document ID List.
The investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original, and attributable, whether the data are handwritten on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical records/electronic health 
records, adverse event (AE) tracking/reporting, protocol-required assessments, and/or drug 
accountability records.
When paper records from such systems are used in place of an electronic format to perform 
regulated activities, such paper records should be certified copies. A certified copy consists of a 
copy of original information that has been verified, as indicated by a dated signature, as an exact 
copy having all of the same attributes and information as the original. 
STUDY INTERVENTION RECORDS
Records for study intervention (whether supplied by BMS, its vendors, or the site) must 
substantiate study intervention integrity and traceability from receipt, preparation, administration, 
and through destruction or return. Records must be made available for review at the request of 
BMS/designee or a Health Authority.
Date: 14 April 2021
63
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
If
Then
Supplied by BMS (or its vendors):
Records or logs must comply with applicable 
regulations and guidelines and should include:
•
amount received and placed in storage area
•
amount currently in storage area
•
label identification number or batch number
•
amount dispensed to and returned by each 
participant, including unique participant 
identifiers
•
amount transferred to another area/site for 
dispensing or storage
•
nonstudy disposition (eg, lost, wasted) 
•
amount destroyed at study site, if applicable
•
amount returned to BMS
•
retain samples for 
bioavailability/bioequivalence/biocomparability, 
if applicable 
•
dates and initials of person responsible for 
Investigational Product 
dispensing/accountability, as per the Delegation 
of Authority Form
Sourced by site and not supplied by BMS 
or its vendors (examples include IP 
sourced 
from 
the 
sites 
stock or 
commercial supply or a specialty 
pharmacy)
The investigator or designee accepts responsibility 
for documenting traceability and study treatment 
integrity in accordance with requirements applicable 
under 
law 
and 
the 
standard 
operating 
procedures/standards of the sourcing pharmacy
BMS or its designee will provide forms to facilitate inventory control if the investigational site 
does not have an established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents, or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture (EDC) tool, eCRFs will be prepared 
for all data collection fields except for fields specific to SAEs and pregnancy, which will be 
Date: 14 April 2021
64
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
reported on the electronic SAE form and Pregnancy Surveillance Form, respectively. If the 
electronic SAE form is not available, a paper SAE form can be used. 
The confidentiality of records that could identify participants must be protected, respecting the 
privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF and SAE/pregnancy CRFs must be promptly reviewed, signed, and dated by 
the investigator or qualified physician who is a sub-investigator and who is delegated this task on 
the Delegation of Authority Form. Sub-investigators in Japan may not be delegated the CRF 
approval task. The investigator must retain a copy of the CRFs, including records of the changes 
and corrections.
Each individual electronically signing eCRFs must meet Sponsor or designee training 
requirements and must only access the BMS EDC tool using the unique user account provided by 
the Sponsor or designee. User accounts are not to be shared or reassigned to other individuals.
MONITORING
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site, they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable.
In addition, the study may be evaluated by the Sponsor or designee internal auditors and 
government inspectors who must be allowed access to CRFs, source documents, other study files, 
and study facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities 
and promptly forward copies of inspection reports to the Sponsor or designee. 
RECORDS RETENTION
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by applicable regulations and guidelines, or 
institution procedures, or for the period specified by BMS or its designee, whichever is longer. 
The investigator (or head of the study site in Japan) must contact BMS prior to destroying any 
records associated with the study.
BMS or its designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed-upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or its designee. 
Date: 14 April 2021
65
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS or a vendor or sourced by the 
investigator), such as partially used study treatment containers, vials, and syringes, may be 
destroyed on site. 
If
Then
Study treatments supplied by BMS (including 
its vendors)
Any unused study interventions supplied by 
BMS can only be destroyed after being 
inspected and reconciled by the responsible 
Study Monitor, unless study treatments 
containers must be immediately destroyed as 
required for safety, or to meet local regulations 
(eg, cytotoxics or biologics).
Partially used study interventions and/or 
empty containers may be destroyed after 
proper reconciliation and documentation. But 
unused IMP must be reconciled by site 
monitor/Clinical Research Associate prior to 
destruction.
If study treatments will be returned, the return 
will be arranged by the responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors; eg, study treatments 
sourced from the site’s stock or commercial 
supply or a specialty pharmacy)
It 
is 
the 
investigator’s 
or 
designee’s 
responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal of study interventions, 
provided that procedures for proper disposal have been established according to applicable federal, 
state, local, and institutional guidelines and procedures, and provided that appropriate records of 
disposal are kept. The following minimal standards must be met:
•
On-site disposal practices must not expose humans to risks from the drug.
•
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
•
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s standard operating procedures and a copy provided to BMS upon request.
•
Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal (eg, incinerator, licensed sanitary landfill, or licensed waste-disposal 
vendor) must be documented.
Date: 14 April 2021
66
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
Accountability and disposal records are complete, up-to-date, and available for the Study 
Monitor to review throughout the clinical trial period.
It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met, the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of non-study 
treatments sourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee. STUDY AND SITE START AND CLOSURE
The Sponsor/designee reserves the right to close the study site or to terminate the study at any time 
for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies have 
been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the Sponsor or investigator may include, but are 
not limited to:
•
Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local Health Authorities, the Sponsor’s procedures, or GCP guidelines
•
Inadequate recruitment of participants by the investigator
•
Discontinuation of further study intervention development
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory authorities, ARSAC, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by the 
applicable regulatory requirements. The investigator shall promptly inform the participant and 
should assure appropriate participant therapy and/or follow-up.
DISSEMINATION OF CLINICAL STUDY DATA
In the European Union (EU), the summary of results and summary for laypersons will be submitted 
within 1 year [6 months for studies including pediatric population] of the end of trial in 
EU/European Economic Area and third countries.
CLINICAL STUDY REPORT
A Signatory Investigator must be selected to sign the Clinical Study Report (CSR). 
For this single site protocol, the Principal Investigator for the site will sign the CSR. 
SCIENTIFIC PUBLICATIONS
The data collected during this study are confidential and proprietary to the Sponsor or designee. 
Any publications or abstracts arising from this study must adhere to the publication requirements 
set forth in the Clinical Trial Agreement (CTAg) governing [study site or investigator] 
Date: 14 April 2021
67
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
participation in the study. These requirements include, but are not limited to, submitting proposed 
publications to the Sponsor or designee at the earliest practicable time prior to submission or 
presentation and otherwise within the time period set forth in the CTAg.
Scientific publications (such as abstracts, congress podium presentations and posters, and 
manuscripts) of the study results will be a collaborative effort between the study Sponsor and the 
external authors. No public presentation or publication of any interim results may be made by any 
Principal Investigator, sub-investigator, or any other member of the study staff without the prior 
written consent of the Sponsor.
Authorship of publications at BMS is aligned with the criteria of the International Committee of 
Medical Journal Editors (ICMJE, www.icmje.org). Authorship selection is based upon significant 
contributions to the study (ie, ICMJE criterion #1). Authors must meet all 4 ICMJE criteria for 
authorship:
1) Substantial intellectual contribution to the conception or design of the work; or the acquisition 
of data (ie, evaluable participants with quality data), analysis, or interpretation of data for the 
work (eg, problem solving, advice, evaluation, insights and conclusion); AND
2) Drafting the work or revising it critically for important intellectual content; AND
3) Final approval of the version to be published; AND
4) Agreement to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Those who make the most significant contributions, as defined above, will be considered by BMS 
for authorship of the primary publication. Sub-investigators will generally not be considered for 
authorship in the primary publication. Geographic representation will also be considered.
Authors will be listed by order of significant contributions (highest to lowest), with the exception 
of the last author. Authors in first and last position have provided the most significant contributions 
to the work. 
For secondary analyses and related publications, author list and author order may vary from 
primary to reflect additional contributions.
Date: 14 April 2021
68
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
APPENDIX 3
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP, AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a 
pre-existing medical condition in a clinical investigation participant administered study 
treatment that does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
•
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
results from other safety assessments (eg, electrocardiograms, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically significant 
in the medical and scientific judgment of the investigator. Note that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term should be updated to be the 
diagnosis.
•
Exacerbation of a chronic or intermittent pre-existing condition, including either an increase 
in frequency and/or intensity of the condition.
•
New conditions detected or diagnosed after study intervention administration, even though 
it may have been present before the start of the study.
•
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
•
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention 
or a concomitant medication. Overdose, as a verbatim term (as reported by the investigator), 
should not be reported as an AE/serious adverse event (SAE) unless it is an intentional 
overdose taken with possible suicidal/self-harming intent. Such overdoses should be 
reported regardless of sequelae and should specify “intentional overdose” as the verbatim 
term.
Events NOT Meeting the AE Definition
•
Medical or surgical procedure (eg, endoscopy, appendectomy); the condition that leads to 
the procedure is the AE.
•
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot be an SAE, even if serious conditions 
are met.
Date: 14 April 2021
69
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
SERIOUS ADVERSE EVENTS
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death.
Is life-threatening (defined as an event in which the participant was at risk of death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe).
Requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE 
below).
NOTE: 
The following hospitalizations are not considered SAEs in Bristol Myers Squibb (BMS) clinical 
studies: 
•
A visit to the emergency room or other hospital department < 24 hours that does not result 
in admission (unless considered an important medical or life-threatening event).
•
Elective surgery, planned prior to signing consent.
•
Admissions as per protocol for a planned medical/surgical procedure.
•
Routine health assessment requiring admission for baseline/trending of health 
status (eg, routine colonoscopy).
•
Medical/surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases.
•
Admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason).
•
Admission for administration of anticancer therapy in the absence of any other 
SAEs (applies to oncology protocols).
Results in persistent or significant disability/incapacity.
Is a congenital anomaly/birth defect.
Is an important medical event (defined as a medical event[s] that may not be immediately 
life-threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the participant or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above). Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm and blood dyscrasias or convulsions that do not result in 
hospitalization. Potential drug-induced liver injury (DILI) is also considered an important 
medical event. (See Section 9.2.8 for the definition of potential DILI.) 
Date: 14 April 2021
70
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Pregnancy and DILI must follow the same transmission timing and processes to BMS as used for 
SAEs. (See Section 9.2.6 for reporting pregnancies.)
EVALUATING AES AND SAES
Assessment of Causality
•
The investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE.
•
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
•
The investigator will use clinical judgment to determine the relationship.
•
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration, 
will be considered and investigated.
•
The investigator will also consult the Investigator’s Brochure and/or product information for 
marketed products in his/her assessment.
•
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
•
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important that 
the investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to the Sponsor.
•
The investigator may change his/her opinion of causality in light of follow-up information 
and send an SAE follow-up report with the updated causality assessment.
•
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.
•
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories: 
•
Mild: An event that is easily tolerated by the participant, causing minimal discomfort and 
not interfering with everyday activities.
•
Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.
•
Severe: An event that prevents normal everyday activities. An AE that is assessed as severe 
should not be confused with an SAE. Severe is a category utilized for rating the intensity of 
an event, and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe.
Date: 14 April 2021
71
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Follow-up of AEs and SAEs
If only limited information is initially available, follow-up reports are required. 
(Note: Follow-up SAE reports must include the same investigator term[s] initially reported.) 
If an ongoing SAE changes in its intensity or relationship to study treatment or if new 
information becomes available, the SAE report must be updated and submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmitting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
REPORTING OF SAES TO SPONSOR OR DESIGNEE
•
SAEs, whether related or not related to study treatment, and pregnancies must be reported 
to BMS (or designee) immediately within 24 hours of awareness of the event.
•
SAEs must be recorded on the SAE Report Form.
−
The required method for SAE data reporting is through the electronic case report 
form (eCRF).
−
The paper SAE Report Form is intended only as a back-up option when the electronic 
data capture system is unavailable/not functioning for transmission of the eCRF to BMS 
(or designee).
♦In this case, the paper form is transmitted via email or confirmed facsimile 
transmission.
♦When paper forms are used, the original paper forms are to remain on site.
•
Pregnancies must be recorded on paper Pregnancy Surveillance Forms and transmitted via 
email or confirmed facsimile transmission.
SAE Email Address: 
SAE Fax Number: 
SAE Telephone Contact (required for SAE and pregnancy reporting): 
.
Date: 14 April 2021
72
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
APPENDIX 4
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
Appendix 4 provides general information and definitions related to Woman of Childbearing 
Potential and methods of contraception that can be applied to most clinical trials. For information 
specific to this study regarding acceptable contraception requirements for female and male 
participants, refer to Section 6.1 of the protocol. Only the contraception methods as described in 
Section 6.1 are acceptable for this study.
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP:
•
Premenarchal
•
Premenopausal female with 1 of the following:
−
Documented hysterectomy
−
Documented bilateral salpingectomy
−
Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•
Postmenopausal female
−
A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 
45 years in the absence of other biological or physiological causes. In addition, females 
under the age of 55 years must have a serum follicle-stimulating hormone (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement therapy (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. Suggested 
guidelines for the duration of the washout periods for HRT types are presented below. Investigators 
should use their judgement in checking serum FSH levels. 
•
1-week minimum for vaginal hormonal products (rings, creams, gels)
•
4-week minimum for transdermal products
•
8-week minimum for oral products
Date: 14 April 2021
73
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
Other parenteral products may require washout periods as long as 6 months. If the serum FSH 
level is > 40 mIU/mL at any time during the washout period, the woman can be considered 
postmenopausal.
End of Relevant Systemic Exposure
End of relevant systemic exposure is the timepoint where the Investigational Medicinal Product 
(IMP) or any active major metabolites have decreased to a concentration that is no longer 
considered to be relevant for human teratogenicity or fetotoxicity. This should be evaluated in 
context of safety margins from the no-observed-adverse-effect level or the time required for 
5 half-lives of the IMP to pass.
METHODS OF CONTRACEPTION
Local laws and regulations may require use of alternative and/or additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent
Failure rate of < 1% per year when used consistently and correctly.a
•
Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulation and/or implantation. (This method of contraception can only be used 
by WOCBP participants in studies where hormonal contraception is permitted by the study 
protocol.)b
−
Oral (birth control pills)
−
Intravaginal (rings)
−
Transdermal
•
Combined (estrogen-and progestogen-containing) hormonal contraception must begin at 
least 30 days prior to initiation of study therapy.
•
Progestogen-only hormonal contraception associated with inhibition of ovulation. (This 
method of contraception can only be used by WOCBP participants in studies where 
hormonal contraception is permitted by the study protocol.)b
−
Oral
−
Injectable
•
Progestogen-only hormonal contraception must begin at least 30 days prior to initiation of 
study therapy.
Highly Effective Methods That Are User Independent
•
Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation and/or implantation. (This method of contraception can only be used by WOCBP 
participants in studies where hormonal contraception is permitted by the study protocol.)b
•
Intrauterine device.
Date: 14 April 2021
74
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
Intrauterine hormone-releasing system (IUS). (This method of contraception can only be 
used by WOCBP participants in studies where hormonal contraception is permitted by the 
study protocol.)b,c
•
Bilateral tubal occlusion.
•
Vasectomized partner 
Male participants will be required to always use a latex or other synthetic condom during any 
sexual activity (eg, vaginal, anal, oral) with WOCBP, even if the participants have undergone a 
successful vasectomy or if their partner is already pregnant or breastfeeding.
•
Sexual abstinence.
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
•
Continuous abstinence must begin at least 30 days prior to initiation of study therapy.
•
It is not necessary to use any other method of contraception when complete abstinence is 
elected.
•
Periodic abstinence (including, but not limited to, calendar, symptothermal, postovulation 
methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea 
method (LAM) are not acceptable methods of contraception for this study. 
NOTES: 
a Typical use failure rates may differ from failure rates when contraceptive methods are used consistently and 
correctly. Use should be consistent with local regulations regarding the use of contraceptive methods for 
participants in clinical studies. 
b Hormonal contraception may be susceptible to interaction with the study treatment, which may reduce the 
efficacy of the contraceptive method. Hormonal contraception is permissible only when there is sufficient 
evidence that the IMP and other study medications will not alter hormonal exposures such that contraception 
would be ineffective or result in increased exposures that could be potentially hazardous. In this case, alternative 
methods of contraception should be utilized. For information specific to this study regarding permissibility of 
hormonal contraception, refer to .Sections 6.1 INCLUSION CRITERIA and 7.7.1 PROHIBITED AND/OR 
RESTRICTED TREATMENTS of the protocol.
c IUSs are acceptable methods of contraception in the absence of definitive drug interaction studies when hormone 
exposures from intrauterine devices do not alter contraception effectiveness. For information specific to this 
study regarding permissibility of hormonal contraception, refer to .Sections 6.1 INCLUSION CRITERIA and 
7.7.1 PROHIBITED AND/OR RESTRICTED TREATMENTS of the protocol..
Less Than Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of > 1% per year when used consistently and correctly.
•
Male or female condom with or without spermicide. Male and female condoms cannot be 
used simultaneously.
Date: 14 April 2021
75
Approved
1.0
v
Approved
1.0
v


Clinical Protocol
CV010-062
BMS-986177
Milvexian
•
Diaphragm with spermicide.
•
Cervical cap with spermicide.
•
Vaginal sponge with spermicide.
•
Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action. (This method of contraception cannot be used by WOCBP 
participants in studies where hormonal contraception is prohibited.)
Unacceptable Methods of Contraception
•
Periodic abstinence (calendar, symptothermal, postovulation methods).
•
Withdrawal (coitus interruptus).
•
Spermicide only.
•
LAM.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of pregnancy information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.6 and Appendix 3.
Date: 14 April 2021
76
Approved
1.0
v
Approved
1.0
v